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ABSTRACT 
Once seen as a disease of wealthy nations, type 2 diabetes mellitus is now 
showing unprecedented growth throughout the world, fueling increases in microvascular 
and macrovascular complications.  A compelling and growing body of evidence suggests 
that glucose intolerance and insulin resistance, hallmarks of the diabetic patient, may be 
driven by chronic inflammation.  In particular, a predominance of visceral fat has been 
associated with enhanced inflammatory cytokine secretion that may contribute to 
enhanced risk of diabetes and comorbid cardiovascular disease in these individuals.  As a 
function of its potency and wide environmental and biological distribution, we 
hypothesized that bacterial lipopolysaccharide (LPS, also known as endotoxin) may 
promote adipose inflammation and concomitant metabolic dysfunction. 
Indeed, expression of the LPS receptor CD14 is enhanced on visceral adipocytes 
of ob/ob mice, paralleling enhanced IL-6 secretion ex vivo.  Furthermore, rosiglitazone-
fed ob/ob mice demonstrated a reduction in CD14 that coordinated with diminished IL-6 
secretion, suggesting a basis for the touted anti-inflammatory effects of this commonly 
employed type 2 diabetes medication.  Mice deficient in components of the LPS signaling 
cascade, namely CD14, TLR4, and MyD88, yielded adipocytes with markedly attenuated 
IL-6 secretion, corroborating the central importance of LPS in adipocyte inflammation 
and supporting the role of this signaling pathway in depot-specific inflammation. 
Despite the prominent role of LPS signaling in adipocyte inflammation, CD14-, 
TLR4-, and MyD88-deficient mice failed to show resistance to diet induced obesity.  
Surprisingly, cd14-/- and tlr4-/- mice had marked glucose intolerance without alteration in 
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total weight or adipose accumulation.  In contrast, myd88-/- mice revealed minor glucose 
intolerance only with high fat diet challenge at an advanced age despite being overtly 
obese.  In cd14-/- and tlr4-/-, but not myd88-/-, mice, an exaggerated rebound to 
hypoglycemia was associated with enhanced norepinephrine secretion, which could be 
abrogated by the adrenergic β-blocker propranolol.  The overlay of these mouse models 
reveals a divergence of phenotypes that demonstrate LPS signaling disruption may lead 
to glucose intolerance and insulin resistance in part due to enhanced sympathoadrenal 
tone, uncovering an essential role of innate immunity in physiological stress and its 
impact upon glucose homeostasis. 
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DIABETES MELLITUS AND THE METABOLIC SYNDROME 
 
Diabetes mellitus, often referred to as diabetes, encompasses a constellation of 
disorders that can be generally characterized by a disturbance in metabolism that leads to 
high circulating glucose (hyperglycemia).  Normally, accumulation of glucose in the 
circulation is counteracted by the secretion of pancreatic insulin that enhances glucose 
uptake by peripheral tissues, such as muscle, liver, and adipose, while suppresses 
formation of endogenous glucose production from metabolic substrates 
(gluconeogenesis) and from breakdown of glycogen (glycogenolysis).  However, a loss 
of insulin supply or insulin action on these peripheral tissues can lead to an imbalance 
that favors glucose excess in the vascular tree. 
Type 1 diabetes, also known as insulin dependent diabetes mellitus (IDDM), is 
believed to be caused by autoimmune destruction of the insulin-producing β-cells of the 
pancreas, leading to an absolute insulin deficiency that typically manifests in the first 
decade of life.  Without an endogenous source of insulin, type 1 diabetes patients rely on 
exogenous administration of insulin in order to maintain glucose homeostasis (Table 
1.1). 
Type 2 diabetes, also known as non-insulin-dependent diabetes mellitus 
(NIDDM), is associated with insulin resistance, referring to the inability of peripheral 
tissues to respond to insulin.  With progressive insulin resistance, it is believed that 
pancreatic β-cells can secrete more insulin in order to compensate for this diminished 
insulin action and maintain glucose homeostasis.  Therefore, despite insulin resistance, 
these individuals may not be overtly diabetic, which is defined clinically by a fasting 
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plasma glucose > 126mg/dL (7.0 mmol/L).  However, it is widely believed that this 
compensated state, though not technically considered diabetes, heralds the beginning of a 
disease process.  In fact, insulin resistance can be found in patients decades preceding 
disease and is a consistent finding amongst diabetic individuals.1-7  Furthermore, 
prospective studies suggest that insulin resistance is the best predictor of diabetes.1,4  
However, recent data suggests that the positive predictive value of insulin resistance may 
be limited to those with a family history or genetic predisposition, such as offspring of 
diabetic patients and Pima Indians.1,4,8 
 
Table 1.1: Diabetes Mellitus: Type 1 vs Type 2 
 
Description  Type I (IDDM)  Type II (NIDDM) 
Etiology  Viral or Immune Destruction 
of β cells of islet 
 Increased Resistance to 
Insulin Action 
Serum Insulin  Low  Variable 
Insulin 
Treatment 
 Always  Sometimes 
Incidence  5-10%  >85% 
Age  <30  >40 
Obesity 
Association 
 No  Yes 
 
This early insulin resistant yet normoglycemic state may progress to diabetes if 
either the β-cells can not keep up with the insulin demand, insulin resistance worsens, or 
likely a combination of the two.  In the diabetic patient, insulin levels may still be above 
normal, but we can consider the system at a relative insulin deficiency that fails to 
maintain normoglycemia.  At late stages in disease, the β-cells may even become 
exhausted due to high insulin demands and undergo apoptosis, leading to β-cell loss and 
reduction of insulin levels below normal.  Hence, the type 2 diabetes patients may have a 
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range of circulating insulin levels contingent on the stage of disease.  In accord, 
pharmacologic treatment in type 2 diabetes can vary from insulin sensitizing compounds, 
including biguanides (glucophage), sulfonylureas (glyburide), and the thiazolidinediones 
(rosiglitazone, pioglitazone), to exogenous insulin administration. (Table 1.1) 
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BURDEN OF DISEASE 
 
Diabetes mellitus is a disease of antiquity, derived from the greek verb derivative 
diabetes that means “a compass, siphon” to represent the characteristic excess in 
urination in individuals with diabetes and later modified with the latin word mellitus that 
means “honey” to describe the sweet taste of urine in these patients.  This theme of sweet 
and copious urination is echoed through many cultures, including ancient Indians that 
diagnosed patients for “sweet urine disease” (Madhumeha) based on the attraction of ants 
to the sugar in the urine.  In fact, modern Korean, Chinese, and Japanese words for 
diabetes are derived from common ancient asian ideographs that translate to “sugar urine 
disease.”9  Despite the long existence of diabetes, it is widely believed that we are in the 
midst of a surge in diabetes supported by both anecdotal clinical evidence and formal 
disease surveillance studies.  Moreover, with advances in average lifespan, the chronic 
complications of diabetes has become evident, representing a significant blight on human 
health and burden to modern day healthcare systems. 
 
UNITED STATES ESTIMATES 
 
In the United States, the American Diabetes Association (ADA) estimates that 1 
million additional people have been diagnosed with diabetes every year for the last 5 
years, culminating in an estimated diabetes population of 17.5 million in 200710.  In the 
United States as well as other industrialized countries, the majority of diabetes (90-95% 
in the US) is classified as type 2 diabetes, which is believed to be the major source of 
global growth.  For the purpose of this thesis, we will primarily address type 2 diabetes 
and will commonly refer to it as simply “diabetes.”  As diabetes prevalence increases 
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with age, this growth can be partially attributed to an aging baby boomer generation.  
However, estimates also predict an increase in diabetes in the young, suggesting that one 
out of every three children born in 2000 will develop diabetes 11.   
Though type 2 diabetes has a strong heritable component, the recent burst in 
diabetes in westernized countries within the span of a generation suggests that there is a 
strong environmental component as well.  It is widely believed that obesity due to dietary 
excess coupled with a decrease in physical activity is the primary culprits in the recent 
diabetes pandemic.  Obesity is defined clinically by the Body Mass Index (BMI) which is 
a ratio of total weight (in kilograms) divided by the square of body height (in meters).  
Based on some population studies, it appears that obesity is proportional to certain 
metrics of diabetes, including fasting glucose and 30-minute insulin concentration 
following oral glucose tolerance test.12 
In the United States, it is estimated that 32.2% of adults are obese, defined as a 
BMI ≥30kg/m2, while 2.8% of men and 6.9% of women are considered extremely obese 
with a BMI ≥40kg/m2 (i.e., greater than 280-lbs with a height of 5 foot 10 inches). 13-20  
The recent rise in obesity in the United States was recorded by The Center for Disease 
Control’s Behavioral Risk Factor Surveillance System (BRFSS) which collected data on 
obesity from 1985 until 2006 through monthly telephone interviews conducted by 
individual state health departments.  In summary, out of the 44 states participating in the 
BRFSS in 1990 there were no states with an equal or greater than 15% obesity 
prevalence.  In contrast, within two decades, only 4 states had an obesity prevalence less 
than 20%, whereas 22 states had an obesity prevalence equal or greater than 25%, 
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including 2 states with an obesity prevalence greater than 30% (Figure 1.1).21-27  In 
support of the linkage between obesity and diabetes, states with the highest prevalence of 
diabetes (>8%) all have an obesity prevalence greater than 25% (Figure 1.2).      
 
 
GLOBAL ESTIMATES 
 
This trend of excess is readily exported to developing countries.  In 2005, 1.6 
billion people were estimated to be overweight (BMI ≥25kg/m2) with 400 million of 
those obese.  Predictions to 2015 elevate these numbers to 2.3 billion overweight 
individuals with 700 million of those obese (Figure 1.3).28  Indeed, the type 2 diabetes 
population shows similar expansion with currently 180 million people afflicted globally 
with an anticipated doubling by the year 2030.28  The mortality attributed to diabetes is 
difficult to quantify because death certificates typically record conditions which are 
predisposed by diabetes, such as cardiovascular disease and renal failure; however the 
World Health Organization (WHO) estimates global diabetes-attributable death at ~2.9 
million on an annual basis.28  With the majority of diabetes deaths currently occurring in 
low- to middle- income countries as well as an anticipated 80% increase in mortality 
expected in upper-middle income countries, diabetes is truly a global pandemic.28 
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1990
No Data
<10%
1998 10%–14%
15%–19%
2006
20%–24%
25%–29% 
≥30%
Figure 1.1: Obesity* Trends Among US Adults – Center for Disease Control and 
Prevention, Behavioral Risk Factor Surveillance System (BRFSS)
(*BMI ≥30, or about 30 lbs. overweight for 5’4” person)
BRFSS is the world’s largest ongoing telephone health survey conducted by 
individual states on a monthly basis.  This data suggests a significant rise in obesity 
in the United States over the last two decades.
8
Figure 1 2: Age-Adjusted Percentage of Adults with Diagnosed Diabetes .         
by State (2005)
States with the highest percentage of diagnosed diabetes tend to correlate 
with states with a higher percentage of obese citizens.
Source:http://apps nccd cdc gov/DDTSTRS/Index aspx?stateId=25&state=. . . .
Massachusetts&cat=prevalence&Data=map&view=TO&trend=prevalence
&id=1
9
The Global Burden of Obesity
2005 2015
1.6 Billion 2.3 Billion
400 Million 700 Million
BMI > 25
in 100 million
BMI >30
in 100 million
Figure 1.3: Global Prevalence of Overweight and Obese Individuals –
Projections to 2015 
Source:  
http://www.who.int/ncd surveillance/infobase/web/InfoBasePolicyMake_
r/reports/Reporter.aspx?id=1
10
  
CLINICAL COMPLICATIONS 
 
Diabetes is a chronic disease that leads to accumulation of damage to the 
vasculature tree, the nervous system, and the kidney.  Major complications can be divided 
into damage to the microvasculature and microvasculature (Table 1.2). 
 
           Table 1.2: Chronic Complications of Hyperglycemia 
 
Microvascular Macrovascular 
Eye Disease  Coronary artery disease 
Neuropathy  Peripheral vascular disease 
Nephropathy  Cerebrovascular disease 
 
Microvascular Complications 
Diabetes predisposes individuals to common eye disorders, increasing the risk of 
glaucoma by 40% and cataracts by 60%.9  However, diabetes can also lead to a group of 
eye maladies, termed diabetic retinopathy, that lead to 12,000-24,000 new cases of 
blindness each year, making diabetes a leading cause of blindness in adults between 20-
74 years old in the United States.9  In a global arena, the WHO estimates that after 15 
years of diabetes 2% of people become blind and 10% will develop visual impairment.28 
Damage to the small vessels supplying nerves (vasa nervorum) leads to diabetic 
neuropathies that can range from changes in sensory sensations to loss of biological 
functions (e.g., erectile dysfunction, impaired gastric motility, and vascular compromise).  
Roughly half of diabetic patients will develop some form of neuropathy.9   
Due to hyperglycemia, 40% of type 1 diabetic patients and 5-15% of type 2 
diabetic patients will develop diabetic nephropathy – the most common cause of end 
stage renal disease in the United States.29,30  Though the cause of diabetic nephropathy is 
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not clear, it is believed that intraglomerular hypertension is an early event contributing to 
glomerular sclerosis.30   
 
Macrovascular Complications 
The macrovasculature refers to the large blood vessels, including the aorta, the 
coronary arteries, and larger vessels of the brain and limbs.  Diabetes is considered an 
anginal equivalent (>20% chance of major coronary events per 10 years), giving diabetic 
patients the same risk profile as an individual with pre-existing heart disease.  This 
roughly translates into a 2-4 times increased risk for heart disease and stroke in 
comparison to individuals without diabetes.  As the majority of our risk assessment 
studies are conducted in American or European populations, the INTERHEART study 
expanded analysis to include 52 countries with varying ethnic and racial backgrounds, 
validating that diabetes is amongst the greatest risks for heart disease (Figure 1.4).  
Indeed, it is estimated that 64% of diabetic patients will succumb to heart disease and 
stroke. 
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INTERHEART STUDY (2004)
OR PAR
ApoB/ApoA1 ratio 3.25 49.2%
(Ab l Li id)
  
norma  p
Smoking 2.87 35.7%
Hypertension 1.91 17.9%
Diabetes 2.37 9.9%
Abdominal obesity 1.12-1.62 20.1%
Regular physical activity 0 86 12 2%   . .
From Young JL Libby P Atherosclerosis Chapter in: Lilly LS editor
Figure 1 4: INTERHEART Study
  ,  .  .     , .  
Pathophysiology of Heart Disease, 4th edition.  Philadelphia: Lippincott Williams & 
Wilkins 2006: 118-140.
 .    
The INTERHEART study identifies major modifiable cardiovascular risks 
from 29,000 survivors of myocardial infarction in 52 countries.  These risks 
are presented as odds ratios (OR), representing the odds of a patient 
suffering an adverse event in comparison to the control, and population 
attributable risk (PAR), representing the proportion of deaths preventable if 
the risk was completely eliminated.
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ETIOLOGY OF DISEASE – GLUCOSE PERSPECTIVE 
 
Despite a predominance of obesity in the type 2 diabetic patient population, it is 
estimated that the majority of obese individuals are not overtly diabetic, suggesting that 
nutrient excess alone is a strong but not singular risk factor for glucometabolic 
dysfunction.31,32  First, we will discuss the predominant “glucocentric” theory in the field 
that focuses on damage caused by high glucose.  Second, we will discuss the 
“lipocentric” view that reveals how lipids can initiate and propagate dysfunction.  Third, 
we will discuss the growing appreciation of the role of inflammation in diabetes 
pathogenesis, potentially serving as a unifying concept in “glucocentric” and 
“lipocentric” viewpoints.   
Excessive circulating plasma glucose is by definition diabetes, but why is this 
extra sugar detrimental?  In fact, glucose is a reactive compound that must be regulated 
from improper reaction and modification of existing proteins, e.g., aberrant glycosylation.  
In addition to traditional biochemical studies, hints from the cells involved in 
microvascular complications suggest that hyperglycemia introduces a cellular stress that 
leads to dysfunction.  Michael Brownlee summarizes the glucocentric perspective into 
four key pathways: 1) Polyol pathway, 2) Advanced Glycation Endproducts, 3) PKC 
activation, and 4) Hexosamine pathway.33 
 
THE POLYOL PATHWAY 
 
The polyol pathway is an important pathway to deal with excess glucose, 
converting intracellular glucose through aldose reductase into sorbitol, which can be later 
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oxidized by sorbitol dehydrogenase to fructose to be used for glycolysis and 
glyconeogenesis.  Aldose reductase serves a similar salutary function to detoxify reactive 
aldehydes created by reactive oxygen species (ROS) into non-reactive alcohols.  
However, in these redox reactions, NADPH is required as a reducing agent; therefore, 
excess activity in these pathways diminishes the available supply of NADPH necessary 
for generating the cellular antioxidant glutathione (GSH) (Figure 1.5).  The combination 
of excess sorbitol, which causes oncotic stress, with diminished GSH, which limits cell 
antioxidant capabilities, is believed to play a role in damage of susceptible cells of the 
microvasculature.  To exemplify the clinical importance of the polyol pathway in 
neuropathies, Engerman et al. found that the aldose reductase inhibitor Sorbinil could 
prevent the loss of nerve conduction velocity in diabetic dogs.34 
 
ADVANCED GLYCATION ENDPRODUCTS 
 
 Advanced glycation endproduct (AGE) formation is believed to be fostered by 
stoichiometric pressures in the high intracellular glucose environments of diabetic 
patients through both auto-oxidation and enzymatic processes, resulting in a reactive 
dicarbonyl that forms a covalent linkage with the amino group of proteins.  This aberrant 
reaction is believed to cause cellular damage via three pathways: 1) alteration of 
intracellular proteins and associated function, 2) alteration of extracellular proteins that 
leads to dysfunction of appropriate cellular reactions, and 3) circulating AGE proteins 
can modify plasma proteins and signal through the receptor of AGE (RAGE) to initiate 
reactive oxygen species and activate nuclear factor kappa B (NFκB) – a prominent pro-
15
From Brownlee M: Biochemistry and molecular cell biology of diabetic complications.  
Nature 414:813-820, 2001
Figure 1.5: The Polyol Pathway
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inflammatory transcription factor leading to release of inflammatory cytokines (IL-1, 
TNFα, IL-6), growth factors (TGFβ, PDGF, M-CSF, GM-CSF), and pro-coagulant 
molecules (thrombomodulin, PAI-1) (Figure 1.6).  The role of AGE inhibitors is actively 
under investigation and early results suggest that they may be effective in reducing 
diabetic microvascular complications.35-41 
 
PROTEIN KINASE C ACTIVATION 
 
 Increased intracellular glucose may serve as a substrate for de novo formation of 
diacylglycerol (DAG) – the activating cofactor for several members of the protein kinase 
C (PKC) family.  The PKC family mediates many processes that may be involved in 
microvascular complications, including alterations in vascular reactivity, permeability, 
angiogenesis, and occlusion that may contribute to retinal and glomerular damage 
(Figure 1.7).  Furthermore, generation of ROS and activation of NFκB enhances 
secretion of pro-inflammatory factors, discussed earlier, that have the potential of 
changing the local microenvironment as well as affect distant tissues.  Despite general 
PKC activation with wide and disparate features, isoform-specific PKC inhibitors have 
shown improvement in retinal and glomerular dysfunction.42,43  Of interest, the first 2 
pathways discussed may also contribute to PKC activation via net increases in reactive 
oxygen species either by shifts in the polyol pathway towards glucose reduction or 
receptor-mediated production with AGE ligation. 
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From Brownlee M: Biochemistry and molecular cell biology of diabetic 
complications.  Nature 414:813-820, 2001
Figure 1.6: Advanced Glycation Endproducts
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From Brownlee M: Biochemistry and molecular cell biology of diabetic 
complications.  Nature 414:813-820, 2001
Figure 1.7: Protein Kinase C Pathway
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THE HEXOSAMINE PATHWAY 
 
 The majority of excess intracellular glucose is destined to form ATP; however, an 
increase in glycolytic intermediates may lead to diversion into other metabolic pathways.  
Exemplified in aortic endothelial cells, hyperglycemia led to the shuttling into the 
hexosamine pathway with the conversion of the fructose-6-phosphate intermediate to 
glucosamine-6-phosphate and then uridine diphosphate N-acetyl glucosamine (UDP-
GlcNAc) (Figure 1.8).  UDP-GlcNAc modification of serine and threonine residues of 
transcription factors can lead to alteration of transcriptional activity.  As an example, 
modification of Sp1 enhances PAI-1 and TGFβ expression, contributing to both 
glomerular and vascular complications (Figure 1.8). 
  
Although each of these pathways contributes to microvascular complications and 
potential exacerbation of macrovascular complications via pro-inflammatory and pro-
coagulant molecules, it is believed that these four pathways can be unified by the 
observation of enhanced intracellular oxidative stress from superoxide production and 
ROS.  In concert with the ability of ROS to enhance stress- and inflammatory-associated 
pathways, ROS inhibition of glyceraldehydes 3-phosphate dehydrogenase (GAPDH) can 
lead to a “back-up” of the glycolytic pathway, diverting intermediates into each of these 
four hyperglycemia-induced pathways (Figure 1.9). 
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From Brownlee M: Biochemistry and molecular cell biology of diabetic 
complications.  Nature 414:813-820, 2001
Figure 1.8: Hexosamine Pathway
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From Brownlee M: Biochemistry and molecular cell biology of diabetic 
complications.  Nature 414:813-820, 2001
Figure 1.9: The Central Role of Reactive Oxygen Species in the Glucocentric
Perspective
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ETIOLOGY OF DISEASE – LIPID PERSPECTIVE 
 
 The common clinical finding of hepatic steatosis and hypertriglyceridemia in type 
2 diabetic patients coupled with epidemiological associations of diabetes with obesity 
suggests that alteration in lipids may contribute to diabetes pathogenesis.  In human 
studies employing MRI-based techniques to quantify intracellular lipid accumulation in 
skeletal muscle, it was shown that high intramyocellular lipids correlated better with 
insulin resistance than traditional metrics, including BMI and total body fat.44,45  Insulin 
resistance with short-term lipid infusions corroborate that excess circulating free fatty 
acids can play a causative role; however, it is not clear what the mechanism of action is 
and whether this approximates obesity in human populations.  One theory proposed by 
Randle suggests that increased β-oxidation of intracellular fatty acids favors a higher 
NADH:NAD+ ratio; thus, preventing forward progress of the glycolytic pathway that 
require NAD+ substrate.  According to Randle’s hypothesis there would be an increase in 
intracellular glucose-6-phosphate levels; however, this theory is challenged by studies 
demonstrating decreased glucose-6-phosphate in lipid-infusion studies of healthy 
individuals as well as in normoglycemic offspring of diabetic parents.46-48 
 To account for this difference, it is believed that free fatty acids may impair 
glucose uptake rather than serve as a competitor for intracellular substrate oxidation.  
Indeed, molecular mechanisms have been proposed demonstrating that free fatty acids 
can lead to inhibition of IRS-1 activity – a key component of the insulin signaling 
pathway necessary for glucose uptake.  However, the direct mechanism of action is 
elusive, but could involve other inhibitors of IRS-1 activity – namely inflammatory 
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cytokines.  In the circulation, free fatty acids have wide access to vascular cells and 
circulating monocytes.  In cell culture systems, free fatty acids, in particular those 
saturated, have been shown to induce inflammatory molecules such as IL-6, IL-8, and 
intercellular adhesion molecule 1 (ICAM-1), which may contribute to tissue insulin 
resistance in many ways, including direct inhibition of the insulin signaling pathway as 
well as recruitment of professional inflammatory cells that can alter the inflammatory and 
metabolic tone.49-58  Indeed, obese individuals are associated with a chronic inflammatory 
state which will be discussed in this emerging viewpoint on diabetes pathogenesis. 
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ETIOLOGY OF DISEASE – INFLAMMATORY PERSPECTIVE 
 
As an ancient disease, empirical treatments for “sugar urine disease” have existed 
anecdotally for generations; however, we are just beginning to understand their molecular 
implications today.  As an example, the bitter melon is a traditional Chinese treatment for 
diabetes that has recently been discovered to harbor potent AMPK activators, which by 
themselves have just recently been appreciated in diabetes pathogenesis over the last 
decade.59  Similarly, the French lilac was used in medieval times to treat diabetes due to 
its active biguanide components.  Although, biguanide-based medications has been is use 
pharmacologically for the last 50 years, its mode of action remains unclear, but may 
involve both AMPK activation as well as novel anti-inflammatory actions in the cells of 
the vascular wall.60,61  Stemming from the innovation of analgesics in 1800s Germany, 
Ebstein observed that the anti-inflammatory salicylates could ameliorate glycosuria, 
representing one of earliest examples implicating inflammation in diabetes pathogenesis 
as well as suggesting that modulation of inflammatory pathways may be a potential 
therapeutic strategy.62  However, further investigations into the role of inflammation 
would remain quiet in the diabetes field for the next century, perhaps muffled by the 
excitement surrounding the discovery of insulin by Frederick Banting and Charles Best.  
We will first discuss the reemergence of the inflammatory hypothesis with 
epidemiological studies linking obesity/diabetes with activation of the innate immune 
response, followed by a review of how inflammatory agents can directly cause insulin 
resistance, and finally a discussion on modulators of inflammation. 
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INFLAMMATORY MARKERS ASSOCIATED WITH DIABETES - THE ACUTE PHASE 
RESPONSE 
 
Epidemiological studies of the 1950s and 1960s would mark the next major 
association of inflammation and diabetes with the finding that the acute phase reactant 
fibrinogen is elevated in obese and diabetic individuals63-65.  Systemic inflammation 
initiates the acute phase response, signaling the liver to produce numerous immune-
modulating proteins, including coagulation factors, complement, C-reactive protein 
(CRP), mannose-binding protein, and serum amyloid A.  Of note, these secreted proteins 
are also known as positive acute-phase proteins in contrast to negative acute phase 
proteins that are decreased, such as albumin and transferrin.66  With the emergence of 
antibody-based diagnostics, the ability to study additional acute phase reactants and 
inflammatory cytokines became possible in large population studies (Table 1.3).  CRP, 
fibrinogen, and PAI-1 have emerged as leading candidates to predict development of 
insulin resistance and diabetes independent of classical risk factors, such as BMI, truncal 
obesity, elevated fasting triglycerides, and even pre-existing insulin resistance in some 
studies.  Although the association of inflammatory mediators, independent of 
anthropometric parameters, with diabetes risk was well characterized, it still remained 
unclear whether inflammation initiated insulin resistance or merely served as a marker.  
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Table 1.3: Increased Acute Phase Reactants and Inflammatory Markers with 
Obesity or Diabetes 
 
Molecule  Cohort 
Fibrinogen  Predict development of diabetes over 5 years independent of BMI, fasting 
triglyceride, insulin sensitivity, HDL, or blood pressure 67-70 
↑ in Insulin resistant individuals with and without diabetes 71 
↑ Microalbuminuric patients72 
↑ Caucasian participants, but not African Americans 73 
↑ BMI, truncal obesity, and bioelectric impedance 74 
↑ in patients from Atherosclerosis Risk in Communities study that develop 
diabetes75 
↔ Eldery patients with new onset diabetes 76 
CRP  Predict development of diabetes over 5 years independent of BMI, fasting 
triglyceride, insulin sensitivity, HDL, or blood pressure 67,68,70 
↑ baseline values in non-diabetics that become diabetes69 
↑ Insulin resistance in non-diabetic individuals 77 
↑ Impaired oral glucose tolerance in non-diabetic individuals 78 
↑ Non-diabetic, hyperinsulemic patients that become diabetic 79 
↑ Microalbuminuric patients72 
↑ BMI, truncal obesity, and bioelectric impedance 74 
↑ Eldery patients with new onset diabetes 76 
Predict development of diabetes in Women’s Health Study independent of 
hormone replacement therapy 80,81 
IL-6  ↑ Caucasian participants, but not African Americans 73 
Predict development of diabetes in Women’s Health Study independent of 
hormone replacement therapy 80,81 
↑ baseline levels in concert with IL-1β prospectively predict diabetes82 
PAI-1  Predict development of diabetes over 5 years independent of BMI, fasting 
triglyceride, insulin sensitivity, HDL, or blood pressure 67,68,70,83 
↑ in insulin resistant individuals with and without diabetes 71 
↑ in Non-diabetic, hyperinsulemic patients that become diabetic 79 
↑ baseline values in non-diabetics that become diabetic independent of BMI or 
insulin sensitivity 69 
Orosomucoid/ 
Sialic Acid 
 ↑ in patients from Atherosclerosis Risk in Communities study that develop 
diabetes75 
WBC  Predict development of impaired fasting glucose and diabetes in non-smokers84 
↑ in Caucasian participants, but not African Americans, predict diabetes 
development 73 
↔ Eldery patients with new onset diabetes 76 
↔ NHANES cohort85 
↑ in patients from Atherosclerosis Risk in Communities study that develop 
diabetes75 
↑ in baseline levels predict increase in insulin resistance nda diabetes 
development in Pima Indians86 
Platelets  ↔ Eldery patients with new onset diabetes 76 
Factor VIIIc  ↔ Eldery patients with new onset diabetes 76 
Albumin  ↓ in patients from Atherosclerosis Risk in Communities study that develop 
diabetes75 
↔ Eldery patients with new onset diabetes 76 
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INSULIN SENSITIVE TISSUES: INFLAMMATORY TARGETS AND SOURCES 
  
Insulin resistance is not uniquely limited to the development of diabetes – its 
clinical presence can be seen in diverse conditions, including lipodystrophy, liver disease, 
polycystic ovarian syndrome, infection, and sepsis.  Inflammatory cues are common 
denominators in these maladies, suggesting their potential role in curbing insulin 
signaling cascades and generating tissue insulin resistance. 
 The role of inflammatory mediators in the molecular pathogenesis of type 2 
diabetes has gained appreciation over the last decade and a half with a seminal paper by 
Hotamisligil et al. revealing that the inflammatory cytokine TNFα can inhibit the insulin 
signaling pathway by prevention of insulin receptor phosphorylation as well as its main 
cytosolic substrate insulin receptor substrate (IRS)-1 in adipose and muscle tissues.87  
Although inflammatory cytokines are soluble and often act distally, the discovery by 
Hotamisligil et al. that TNFα was expressed by adipose tissue itself opened up new 
possibilities where cytokines can act in a paracrine or autocrine fashion – effectively 
increasing physiological concentrations when isolated to a local environment.88 
We will examine current literature supporting the ability of inflammatory 
cytokines and mediators to alter insulin signaling pathways and glucose regulation in 
peripheral tissues, namely the liver, skeletal muscle, and adipose. 
 
Liver 
 The importance of the liver in glucose homeostasis is exemplified by both 
infectious and non-infectious etiologies of liver dysfunction, which commonly present 
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with hepatic insulin resistance and impaired whole body glucose regulation.  In fact, 
nonalcoholic fatty liver disease (NAFLD) is believed to be present in 5% of the general 
population and about 25% of the obese and type 2 diabetes populations, highlighting the 
liver’s important role in glucose homeostasis in the human population.89-92 
 Productive insulin signaling in the liver inhibits hepatic gluconeogenesis and 
glycogenolysis, which in sum can be termed hepatic glucose production (HGP).  In the 
fed state, insulin binds to the insulin tyrosine kinase receptor which phosphorylates 
tyrosine moieties on insulin receptor substrates (IRS), activating multiple parallel 
cascades: 1) MAPK cascade to activate Erk leading to gene transcription, and 2) PI3K 
cascade to activate Akt leading to protein synthesis through mTOR, to lipolysis through 
PKA and HSL, to GLUT4 exocytosis through AS160, and to inhibition of glycogen 
synthesis and fatty acid synthesis through GSK-3.  As a central metabolic hub, the liver 
accepts gluconeogenic substrates and free fatty acids from other tissues of the body - 
liberated during fasting states in order to provide additional glucose.  Given the reciprocal 
state when fed, insulin-mediated suppression of substrate release in the periphery may 
have accounted for decreased HGP.  However, this non-hepatic (indirect) insulin effect 
on HGP has been partially discounted by the liver-specific insulin receptor knockout 
(LIRKO) mouse, which demonstrated the inability of insulin to suppress HGP despite 
functional peripheral insulin action, favoring a model where hepatic (direct) insulin 
action is an essential component for HGP regulation.93  
Early studies of inflammation in hepatic glucose output employed injection of 
Escherichia coli endotoxin – a potent stimulus of multiple inflammatory cytokines.  
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Indeed, injection in both normoglycemic and diabetic rats led to marked elevation in 
serum glucose associated with depletion in hepatic glycogen content.94,95  To specify 
which inflammatory player may be involved, in vitro experiments in primary murine 
hepatocytes and human HepG2 liver cell lines demonstrated that pretreatment with IL-6 
led to a time-dependent decrease in IRS-1 tyrosine phosphorylation and Akt 
phosphorylation – key events in the insulin signaling pathway.96  Moreover, pre-infusion 
of IL-6 in vivo prior to hyperinsulemic-euglycemic clamping shows no changes in basal 
HGP, but following insulin administration, demonstrates a reduced ability to suppress 
HGP.97  On a molecular level, the inability of insulin to suppress HGP in IL-6 pretreated 
mice was associated with a 50% decrease in insulin-stimulated IRS-2-associated PI3K 
activity.97,98  However, co-infusion with the anti-inflammatory cytokine IL-10 was able to 
restore hepatic insulin sensitivity without changes in basal metabolism.97 
 TNFα neutralization utilizing TNF receptor (TNFR)- IgG fusion proteins in the 
Zucker (fa/fa) rat model of obesity failed to demonstrate in vivo improvement in hepatic 
insulin signaling.87  However, studies by Cheung et al. using adenoviral strategies to 
express a chimeric fusion protein using human TNFR with mouse IgG demonstrated 
improvement in hepatic insulin resistance in obese animals, without changes in insulin 
receptor tyrosine phosphorylation.99  On the other hand, enhancing TNFα via exogenous 
infusion in obese Zucker rats corroborated hepatic insulin resistance, suggesting TNFα 
could inhibit insulin action distal to insulin receptor phosphorylation.100  However, in 
vitro studies in rat hepatoma Fao cells suggests that TNFα inhibits insulin-induced 
tyrosine phosphorylation of the insulin receptor and IRS-1.101  Although the mechanism 
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of action remains unclear as well as complicated by the ability of TNFα to induce other 
cytokines, it appears that TNFα is sufficient to induce hepatic insulin resistance. 
 In response to inflammatory stimuli, negative feedback is promoted by a group of 
proteins names suppressors of cytokine signaling (SOCS).  In vitro, IL-6-induced insulin 
resistance in HepG2 cells correlated temporally with increases in SOCS-3 
expression.102,103  To highlight the relevance of inflammation in obesity and their shared 
role in insulin resistance, Ueki et al. used  obesity as well as LPS-induced endotoxemia 
models in parallel to demonstrate similar increases in hepatic and muscle SOCS 
associated with hepatic insulin resistance that could be recapitulated with adenoviral-
mediated SOCS-3 overexpression alone.104 
IL-6 may affect glucose homeostasis through its close interaction with STAT3.  
Loss of hepatic STAT3 abrogates insulin-mediated suppression of gluconeogenic 
enzymes, while reconstitution via adenovirus ameliorates this hepatic insulin 
resistance.105  On the other hand, constituitive activation of hepatic STAT3 leads to 
unimpeded gluconeogenic suppression with diminished blood glucose and insulin.105  In 
studies of diet and genetic obesity, STAT3 activity and hepatic insulin resistance were 
reduced by IL-6 neutralizing antibodies, exemplified by a 3-fold increase in insulin-
induced suppression of gluconeogenesis and a 50% increase in hepatic Akt 
phosphorylation.106.  The role of IL-6 and STAT3 in glucose homeostasis has central 
nervous system (CNS) origins as intracerebral ventricular (ICV) injection of insulin 
suppresses HGP, while loss of hepatic STAT3 or IL-6 impairs this normal response.107 
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The liver is an important organ mediating whole body glucose homeostasis with 
significant potential intersections with inflammation.  In addition to the systemic 
inflammatory state in obesity, primary liver inflammation, e.g., chronic hepatitis C virus 
(HCV) infection, is associated temporally with insulin resistance, while HCV clearance 
with diminished inflammation parallels improvement in insulin sensitivity in these 
patients.108-110  Moreover, transgenic models expressing HCV core protein alone was 
sufficient to produce insulin resistance that was associated with elevated TNFα.111  
Therefore, to appreciate the role of inflammation in insulin resistance and the importance 
of the liver in glucose homeostasis, we need only look to other clinical examples. 
 
Skeletal Muscle 
Skeletal muscle is the main site of insulin-stimulated glucose uptake, serving as 
an important glucose sink in the body with significant glycogen storage capability.112  
However, muscle-specific insulin receptor knockout mice (MIRKO) remain 
normoglycemic due to a redistribution of glucose uptake function to adipose tissue – 
exemplified by 3-fold increase in insulin-stimulated glucose uptake and enhanced adipose 
mass.113  Therefore, although it is helpful to organize our thoughts on specific roles each 
tissue plays, there is remarkable plasticity in the system in order to maintain glucose 
homeostasis. 
Multiple modalities of TNFα neutralization has been employed in models of 
obesity, including direct and adenoviral-mediated expression of TNFR-IgG fusion 
proteins and genetic knockouts, indicating a clear role of TNFα in skeletal muscle insulin 
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resistance with inhibition at the level of the insulin receptor and IRS.87,88,99,100,114  Similar 
mechanisms of action were confirmed in human vastus lateralis muscles from healthy 
volunteers injected with TNFα, demonstrating direct suppression of insulin receptor 
signaling and glucose uptake in human skeletal muscle via inhibition of Akt-mediated 
phosphorylation of Akt substrate 160 (AS160).115  Again, TNFα-induced insulin 
resistance in skeletal muscle may also be mediated by upregulation of SOC-3.116  In sum, 
TNFα-mediated inhibition of skeletal muscle insulin signaling in rodent models shows a 
promising opportunity for anti-TNFα treatments in human diabetes, but their 
effectiveness remains unclear.117 
Working skeletal muscle, e.g. during exercise, enhances expression of pro- and 
anti-inflammatory cytokines, but IL-6 secretion is the most prominent.118,119  IL-6 
secretion is proportional to the duration and intensity of exercise, and may be in part 
mediated by release of epinephrine during exercise which was demonstrated to enhance 
IL-6 secretion in vitro.118,120.  Loss of IL-6 in genetic knockout models led to mature-
onset obesity with glucose intolerance that could be reversed with exogenous IL-6 
replacement, suggesting beneficial functions in contrast to those described earlier in the 
liver.121  IL-6 administered centrally enhanced energy expenditure and fat loss, while low 
IL-6 in cerebrospinal fluid was associated with severe obesity in humans – suggestive of 
IL-6 action in the CNS.  The role of IL-6 in whole body glucose homeostasis is likely 
tissue-specific, but remains an intriguing candidate as a muscle-derived cytokine 
enhanced by exercise and pluripotent in action. 
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Adipose Tissue 
 Expansion of adipose tissue is the most blatant feature associated with human 
obesity.  Traditionally, adipose tissue has been viewed as an inert tissue that merely 
harbors excess energy in the form of calorie-dense lipids.  However, recent studies have 
elucidated that adipose is indeed an endocrine organ, mediating diverse processes from 
energy metabolism and feeding behavior to vascular tone and hemostasis (Figure 1.10).  
In the last decade and a half, adipocytes have been shown to be professional secretors of: 
1) traditional inflammatory cytokines, 2) adipose-specific cytokines also known as 
adipokines, and 3) chemokines that direct other cell types into adipose tissue. 
 TNFα was one of the first cytokines shown to be expressed in adipose and 
enhanced in rodent and human obesity, paralleling systemic and tissue insulin resistance 
closely.88,122  Indeed, similar to experiments discussed in skeletal muscle, enhanced 
TNFα with obesity or direct infusion was able to elicit insulin resistance in adipose tissue 
and subsequently reversed with TNFα antagonists and genetic deletion.87,114  Similar to 
skeletal muscle, TNFα action may be mediated by SOCS-3 expression.116 
Several agonists common in the adipose microenvironment induce IL-6 secretion, 
including hormones (insulin, TSH, GH), inflammatory stimuli (TNFα, LPS, IL-1, IL-6, 
Prostaglandin D2), the fatty acid palmitate and the β-receptor agonist isoproterenol.123-131  
Sustained adipocyte exposure to IL-6  in vitro led to a feed forward mechanism that 
amplified IL-6 concentration from endogenous sources.123,124  Though insulin resistance 
was a common end result of IL-6 treatment in both 3T3-L1 and 3T3-F442A adipocytes, 
the mechanism of action is conflicted with mixed results suggesting downregulation of 
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Figure 1 10: Adipose as an Endocrine Organ
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 .      
Former views of adipose as an inert storehouse for lipids has been 
supplanted with recent discoveries that adipose is in fact a major source of 
secreted factors.  The variety of factors secreted include inflammatory 
cytokines, chemokines, thrombogenic factors, metabolic hormones, sex 
hormones, mediators of vascular tone, and adipocytokines.      
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insulin receptor β, IRS-1, and GLUT-4 via translational or post-translational 
mechanisms.123,124  IL-6 may also contribute to insulin resistance via the paracrine 
inhibition of the adipocyte-restricted insulin-mimetic visfatin expression in 3T3-L1 
adipoctyes. 132 
Although IL-1β has a prominent role in other chronic inflammatory conditions, 
the in vivo contribution to tissue-specific glucose tolerance is difficult to disassociate 
from roles of IL-1 in food intake, lipid metabolism, and obesity.133,134  However, 
continuous addition of IL-1β to 3T3-L1 adipocytes in vitro led to an Erk-dependent 
downregulation of IRS-1 mRNA which could be prevented with an Erk inhibitor.135 
 Inflammatory mediators clearly can modulate insulin signaling pathways with 
hepatocyte-, myocyte-, and adipocyte-derived cytokine production representing an 
effective local source of inflammatory stimuli; however, the role of adipose tissue in 
mediating systemic inflammatory tone remains controversial.  Emerging data using a 
model of inducible fat-specific apoptosis (FAT Apoptosis Through Triggered Activation 
of Caspase-3; FAT-ATTAC) has led to insight into the role of adipose in directing 
systemic inflammation.  Injection of the potent inflammatory stimulus LPS normally 
leads to rapid systemic inflammation and acute insulin resistance; however, fatless FAT-
ATTAC show marked attenuation of LPS-induced inflammation, alluding to the 
importance of adipose in systemic inflammatory responses.136 
Though the inflammatory hypothesis in diabetes is not a new theory, the ability to 
test the molecular intersections of these two areas has required both the development of 
the insulin signaling pathway as a framework for investigation as well as advancements 
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in recombinant protein and immunological technologies in order to create investigatory 
tools.  Nonetheless, the role of inflammation in insulin-sensitive peripheral tissues is an 
active area of development and there is significant confidence that additional roles of 
inflammatory mediators in metabolic homeostasis will be uncovered. 
 
INFLAMMATION-DIRECTED INSULIN RESISTANCE – MOLECULAR BLUEPRINT 
 
Though cytokine-induced insulin resistance is a concept in its infancy with the 
majority of studies conducted in the last decade, convergence of insulin signaling and 
inflammatory pathways have been revealed.  In particular, the Jnk and NFκB 
inflammatory pathways intersect with components of the insulin signaling cascade. 
 C-Jun N-terminal kinase (Jnk) is a stress-responsive kinase, increasing in activity 
with cytokine exposure, intracellular oxidative stress, and free fatty acids.  Activated Jnk 
phosphorylates IRS-1 at serine 307, inhibiting productive insulin-mediated tyrosine 
phosphorylation.137  In contrast, substitution of alanine for serine at the 307 position on 
IRS abrogates Jnk-induced serine phosphorylation and prevents TNFα-mediated 
inhibition of insulin signaling.137  In accord, Jnk-1 deficient mice are refractory to diet-
induced obesity with enhanced insulin sensitivity (Figure 1.11).138 
Nuclear Factor kappa B (NFκB) is the prototypical stress-responsive transcription 
factor that resides in the cytosol bound to inhibitor of kappa B (IκBα).  Inflammatory 
cytokines, AGE, fatty acids, and bacterial lipopolysaccharides activate inhibitor of kappa 
B kinase (IKK), which phosphorylates IκBα to foster disassociation and allow NFκB 
nuclear translocation, driving transcription inflammatory cytokines and chemokines such 
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as IL-1, IL-6, IL-18, TNFα, and MCP-1.  Of note, NFκB may also transcribe anti-
inflammatory molecules as well, including IL-10 and manganese superoxide dismutase.  
Similar to Jnk, IKK phosphorylates IRS-1 at serine 307  in both cell models as well as 
using recombinant proteins.139  Attenuating IKK activity via salicylate treatment or 
heterozygous gene disruption was sufficient to prevent diet-induced obesity and improve 
insulin sensitivity.140,141  On the other hand, low-level constitutive expression of IKKβ in 
hepatocytes was sufficient to approximate the diet-driven insulin-resistant phenotype; 
however, hyperglycemia and systemic insulin resistance may have stemmed from severe 
hepatic insulin resistance.142  Despite direct intracellular interaction of IKK and IRS-1 in 
this model, systemic IL-6 neutralization was still beneficial, suggesting that secreted 
factors as well as intracellular events both influence insulin resistance.142(Figure 1.11) 
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INFLAMMATION AS A UNIFYING CONCEPT IN INSULIN RESISTANCE: WHAT FANS THE 
FLAMES? 
 
 Numerous lines of evidence suggest that inflammation is present with insulin 
resistance in both animal models as well as human disease.  The discovery that peripheral 
insulin-sensitive tissues themselves can produce many of these inflammatory mediators 
has put forward an intriguing hypothesis of inflammation-driven insulin resistance.  
Nonetheless, what environmental or biological cue drives this inflammatory insult to the 
point of insulin resistance?   
 Vascular inflammation has close clinical and molecular relationships with 
diabetes that maintains relevance for future inquiries; however, it may be outside the 
scope of this thesis.  Therefore, we will merely summarize the main points that: 1) 
vascular smooth muscle cells (SMC) and endothelial cells (EC) normally maintain a non-
inflammatory, non-thrombogenic vascular surface that limits leukocyte adhesion and 
lipid penetration (Figure 1.12), 2) activation of SMC and EC by inflammation (e.g., 
cytokines, LPS, ROS) stimulates feed forward cytokine expression, pro-thrombotic 
molecules, chemokines, and leukocyte adhesion molecules (Figure 1.12), 3) concomitant 
hyperglycemia in patients fosters accumulation of glycated LDL in the vessel wall, which 
serves as a potent inflammatory stimulus, and 4) the “activated” vessel wall recruits 
macrophages that serve as an important source of pro-inflammatory cytokines.  Truly, the 
cast of players in any tissue goes beyond the parenchyma to include the cells of the 
vasculature that serve as the bouncers of the tissue – denying and directing entrance of 
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From Young JL, Libby P.  Atherosclerosis.  Chapter in: Lilly LS, editor.  
Pathophysiology of Heart Disease, 4th edition.  Philadelphia: Lippincott Williams 
& Wilkins 2006: 118-140.
Figure 1.12: Endothelial and Smooth Muscle Cell Activation by 
Inflammation. 
(A) Normal endothelial and smooth muscle cells maintain the strength and 
elasticity of the normal arterial wall, while limiting immune cell infiltration in the 
uninjured state.  (B) Inflammatory “activation” of these vascular cells corrupts 
their normal function and favor pro-atherogenic mechanisms (e.g. immune cell 
infiltration) that drive plaque development. IL-1, interleukin-1; TNF-a, tumor 
necrosis factor-a; oxLDL, oxidized LDL; ROS, reactive oxygen species.
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circulating cell populations.  A more detailed description of these processes is provided in 
the context of atherosclerosis in the Supplement. 
 Glucocentric and lipocentric perspectives are not mutually exclusive of the 
inflammatory perspective.  First, we will discuss how the cornerstones of diabetes, 
namely hyperglycemia, hyperlipidemia, insulin, and leptin, modulate inflammation.  
Second, we will introduce the LPS signaling pathway, which has been employed 
previously as an experimental method to drive inflammation-induced insulin resistance, 
but also represents an attractive etiologic agent that is both ubiquitous and potent.  In 
conclusion, we will address whether inflammation is the driver or the bystander as well 
as present the specific aims for our scientific inquiry.    
 
MODULATORS OF INFLAMMATION 
  
Inflammation is a normal physiologic response to injurious stimuli with the 
intention to protect from further damage as well as initiate a healing response.  
Appropriately, the number of noxious stimuli that may activate inflammation are diverse 
and numerous.  But when does an initially salutary response lead to pathophysiological 
consequences?  We will address a subset of these pro- and anti- inflammatory signals that 
are relevant to diabetes from the glucocentric and lipocentric perspectives, demonstrating 
their overlap with inflammatory mechanisms. 
 
Hyperglycemia 
 Excess glucose is the primary inciting factor in the glucocentric perspective.  
Beyond direct contribution of activated PKC and AGE formation in activating the pro-
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inflammatory transcription factor NFκB, all four pathways outlined by Brownlee have 
been linked through a common denominator – reactive oxygen species (ROS).  Increased 
intracellular glucose and processing through the electron transport chain leads to an 
excess of free electrons that must be donated to molecular oxygen to form oxygen 
radicals.  The elimination of these radicals via increased degradation by manganese 
superoxide dismutase, inhibition of proximal steps of the electron transport chain, or 
uncoupling of the mitochondrial gradient prevents hyperglycemia-induced activation of 
major inflammatory pathways.143  Indeed, in vitro culturing of 3T3-L1 in high glucose 
media leads to excess ROS production associated with IL-6 production.144  However, we 
must take into account that this process of hyperglycemia-induced ROS generation with 
subsequent inflammatory activation may not be a cell-specific response, expanding 
potential sources of inflammation to many if not the majority of cells. 
 
Hyperlipidemia 
 Elevated free fatty acids are common in the type 2 diabetes clinical picture with 
concordant elevation of triglycerides – a potential culprit linking the western diet that is 
high in saturated fats with the obesity and diabetes epidemic.  As a metabolic substrate, 
excess fatty acid oxidation in peripheral tissues can also generate oxidative stress similar 
to hyperglycemia.145  Additionally, fatty acid metabolites are potent activators of PKCθ, 
mediating acute fatty-acid induced insulin resistance with concordant serine 
phosphorylation of IRS-1 in skeletal muscle.146  Moreover, increased accumulation of 
fatty acid metabolites with transgenic overexpression of lipoprotein lipase in skeletal 
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muscle and liver lead to tissue-specific insulin resistance.147  However, it remains unclear 
whether PKCθ acts directly on the insulin signaling pathway or indirectly via its 
prominent interactions with the NFκB pathway.  Saturated fatty acids, in particular 
palmitic acid, are considered pro-inflammatory with NFκB induction in vascular cells 
and macrophages.49  The pro-inflammatory nature of this fatty acid may be reflected in 
the association of palmitic acid, but not other free fatty acids, with serum IL-6 levels in 
human subjects.49 
 
Insulin and Leptin 
Despite insulin’s prominent role in glucose metabolism, it has been increasingly 
recognized that hyperinsulinemia associated with pre-diabetics and diabetics prior to β 
cell islet loss may continue to stimulate inflammation.148,149  However, other studies 
suggest that early insulin treatment in diet- and streptozocin-induced diabetes in rats 
attenuated NFκB activity with coordinate reductions in TNFα and IL-1β mRNA 
expression in the liver and TNFα in muscle.150  Whether insulin is pro- or anti-
inflammatory is unclear, and likely mired in its role in metabolism, but the bulk of studies 
suggest that insulin does have inflammation-modulating effects.   
  Acutely, leptin can be increased by pro-inflammatory stimuli, such as LPS, IL-1, 
and TNFα.151-153  Conversely, leptin can potentiate the acute phase response, which is 
attenuated in leptin-deficient (ob/ob) mice stimulated with LPS, resulting in diminished 
TNFα and IL-6 expression.154-156  Paradoxically, leptin-deficient mice also demonstrate 
increased sensitivity to LPS-induced toxicity, including rapid hepatosteatosis associated 
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with altered cytokine expression.156  Of interest, female rodents are more susceptible to 
LPS-induced toxicity and engenders the discussion of gender-specific effects that will be 
important in therapeutic applications.156  Thus, similar to insulin, leptin is a double-agent 
likely subserving both pro- and anti-inflammatory pathways. 
 
LIPOPOLYSACCHARIDE SIGNALING PATHWAY 
 
Lipopolysaccharide (LPS) is a common component of gram negative bacteria, 
consisting of the Lipid A portion embedded in the outer wall, the core oligosaccharide, 
and the polysaccharide O-antigen.  LPS is an amphiphilic molecule that forms aggregates 
and micelles in solution; thus, requiring carrier proteins such as albumin to facilitate 
cellular response.157,158  LPS association with LPS binding protein (LBP) with subsequent 
delivery to membrane bound CD14 further enhances the cellular response, which is 
typified in macrophages as an inflammatory response with release of pro-inflammatory 
cytokines, such as TNFα, IL-1, IL-6, and IL-8. 159-165  As CD14 lacks a transmembrane 
signaling domain, it relies on interaction with MD2 and TLR4 to activate intracellular 
pathways.  The cytosolic portion of TLR4 has Toll-interleukin-1 receptor (TIR) domains 
that can recruit different sets of adaptors that can be roughly broken down into: 1) 
myeloid differentiation primary response gene 88 (MyD88)-dependent pathway which 
utilizes the TIR domain-containing adaptor protein (TIRAP) and MyD88, and 2) MyD88-
independent pathway which utilizes TIR domain-containing adaptor inducing IFN-β 
(TRIF) and TRIF-related adaptor molecule (TRAM) (Figure 1.13).  The MyD88-
dependent pathway leads to nuclear translocation of NFκB and induction of Ap-1 
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transcription factors, leading to pro-inflammatory secretion of TNFα and IL-6.  Whereas, 
the MyD88-independent pathway leads to dimerization and nuclear translocation of 
IRF3, leading to expression of IFNα, IFNβ, and IFNω (Figure 1.13).  Both these 
responses are effective and appropriate for combating bacteria; however, unimpeded LPS 
signaling and cytokine expression can lead to sepsis.  Therefore, mechanisms of negative 
regulation are necessary to prevent collateral damage to the host.  For the sake of our 
discussion we will only mention that SOCS-1 is involved in TIRAP ubiquitination and 
degradation, while loss of SOCS-1 leads to enhanced LPS-stimulated cytokine 
production in macrophages.166     
 
INFLAMMATION IN INSULIN RESISTANCE – CHICKEN OR THE EGG 
 
 Clinical and experimental studies confirm the prominent role that inflammation 
can play with insulin resistance, obesity, and type 2 diabetes; however, whether 
inflammation is a causative factor, rather than merely an outcome, remains unclear.  
Additionally, it must be stressed that a number of in vivo data is derived from mice and 
rats that have been specifically selected for their susceptibility to developing glucose 
intolerance, insulin resistance, or specific microvascular or macrovascular complications.  
Indeed, even diet induced obesity models rely on the genetic background of the C57Bl/6J 
that predisposes these mice to glucose intolerance.  Of interest, C57Bl/6 mice were 
initially chosen for their pattern of response to infection which led to primarily secretion 
of Th1 cytokines – a subset of cytokines implicated for their pro-inflammatory 
contribution to chronic inflammatory diseases, such as asthma, arthritis, and 
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atherosclerosis.  Nonetheless, in concert with studies in humans, it remains probable that 
inflammation contributes to multiple etiologic theories of diabetes pathogenesis and 
represents a fertile area of discovery for future molecular insights and therapeutic 
strategies. 
 To add to the current body of knowledge, we will investigate the role of the LPS 
signaling pathway in murine models of glucose intolerance and insulin resistance.  First, 
we will investigate whether the LPS receptor CD14 can account for the inflammatory 
potential of visceral adipose.  Second, we will describe the metabolic phenotype of mice 
deficient in components of the LPS signaling cascade, including CD14, TLR4, and 
MyD88, to ascertain their role in whole body glucose homeostasis and as targets for 
systemic treatment. 
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SUMMARY 
 
Type 2 diabetes mellitus, known as non-insulin-dependent diabetes mellitus 
(NIDDM) or adult-onset diabetes, currently comprises 90-95% of all diagnosed diabetes, 
with an alarming increase in incidence among youth.11  In the United States, current 
estimates approximate that one-third of children born in 2000 will develop diabetes.11  
Obesity is believed to contribute to type 2 diabetes pathogenesis in part due to enhanced 
secretion of adipose-derived inflammatory cytokines, such as IL-6 and TNFα.167-170  
Moreover, clinical and research oriented studies suggest that organ-associated adipose, so 
called visceral adipose, is a stronger predictor of diabetes incidence and concomitant 
macrovascular complications.12,171  With studies by Wiedermann et al. suggesting a role 
of bacterial-derived lipopolysaccharide (LPS) in fueling systemic inflammation, we 
investigated whether the classical LPS receptor CD14 may be involved in determining 
adipose inflammatory potential.172  Indeed, CD14 expression is enhanced on visceral 
adipocytes of ob/ob mice, which can be downregulated by in vivo rosiglitazone treatment.  
In isolated adipocytes, diminished CD14 expression in subcutaneous and rosiglitazone-
treated visceral adipocytes leads to a parallel reduction in ex vivo IL-6 secretion.  Mice 
deficient in components of the LPS signaling cascade, namely CD14, TLR4, and MyD88, 
yield adipocytes with diminished capacity to secrete IL-6.  Therefore, these studies are 
the first to report the importance of LPS signaling in adipocyte IL-6 secretion and 
potentially represent a molecular explanation for differences in adipose inflammation and 
pathogenicity.       
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INTRODUCTION 
 
The Venus of Willendorf (c. 25,000-20,000 B.C.) is one of the earliest pieces of 
art, depicting a plump, curvaceous form that was to represent fertility and health; it was 
not till later Aegean art that figures of female health encompassed slim and slight forms 
(Figure 2.1).173  Though obesity through the millennia has maintained varying positive 
and negative connotations – both social and medical, it was not until 1959 that the 
medical insurance industry attempted to define an ideal, or in other words healthy, weight 
for individuals.174  In recent years, the World Health Organization (WHO) warns that 
obesity has penetrated high-, low-, and middle-income countries alike, driving a “double 
burden” in developing countries with continuing issues of infectious disease and 
undernutrition now coupled with concurrent overnutrition that fuels chronic disease, such 
as diabetes and heart disease.32 
Building upon compelling epidemiological evidence, scientific studies suggest 
that obesity contributes to pathophysiological changes that fuel Type 2 diabetes mellitus 
development.  Empirical observations recognized that adipose distribution also 
contributes to risk.175,176  Those who carried excess fat in their abdomen (so called 
“apple-shaped”) were more prone to hypertension, cardiovascular disease, and diabetes 
than those who deposited excess fat in their hips and thighs (so called “pear-shaped”).  
The “apple-shape” occurs in part due to adipose deposits around the organs of the 
abdomen, which subsequently augments abdominal protrusion.  Such organ-associated 
fat is called visceral adipose in contrast to subcutaneous fat, which is located underneath 
the skin.  Magnetic resonance imaging (MRI) and computed tomography (CT) scanning 
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Figure 2.1:  Ancient Perceptions of Health and Fertility
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culture that saw obesity as a sign of health and fertility.  It was not until roughly 
20,000 years later that it is believed that lithe and slender figures were seen as 
comparable, if not preferable, body types.
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has been used to delineate visceral from subcutaneous fat depots, reaffirming 
quantitatively that visceral adiposity is a strong risk factor for cardiovascular disease and 
diabetes.177-179  Moreover, recent studies by Goodpaster et al. demonstrate that even in 
normal weight individuals, visceral adiposity was highly associated with the metabolic 
syndrome, a clustering of risk factors that typically precede the development of both 
cardiovascular disease and overt diabetes.180  
In contrast to the previous perception of adipose as an inert lipid storehouse, 
adipose is in fact an important organ orchestrating metabolic, endocrine, and 
inflammatory systems.181  For example, transgenic overexpression of adiponectin, a 
protein restricted to adipocytes, ameliorates both diabetes in the ob/ob mouse model and 
atherosclerosis in the ApoE-deficient mouse model.182,183  Adiponectin and leptin (and 
potentially visfatin, resistin, and adipsin) are members of an emerging class of adipokines 
- secreted proteins primarily produced by adipocytes.184 Nonetheless, adipose tissue 
remains an important source of classical inflammatory cytokines, including TNFα, IL-6, 
IL-8, IL-10, MCP-1, and IL-1 receptor antagonist.181  It fact, it is believed that higher 
expression of these inflammatory cytokines account for the higher risk for disease in 
visceral fat.20,175,176  Thus, in addition to its prominent role in metabolism, adipose tissues 
serve as an important source of secreted factors that may shape progression or regression 
from diseases associated with chronic subclinical inflammation, such as diabetes and 
atherosclerosis.   
Bacterial lipopolysaccharides (LPS; also known as endotoxin) are prominent 
inflammatory agonists that can induce inflammation in trace amounts.  LPS binds to LPS 
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binding protein (LBP) in the serum and is transferred to CD14 on the cell membrane 
where association with MD2 and TLR4 lead to intracellular signaling transduction, 
initiating inflammation and pathogenic response; hence, representing an important arm of 
innate immunity.  Recently, TLR4 has been found to be increased on adipocytes with 
3T3-L1 differentiation and in the db/db genetic model of obesity, conferring sensitivity to 
LPS and allowing production of inflammatory cytokines, such as TNFα and IL-6.185  
Given the potency of LPS as an inflammatory stimulus as well as early studies 
demonstrating the functional presence of TLR4 on adipocytes, we sought to investigate 
whether the classical LPS-receptor CD14, which serves in a complex with TLR4, could 
play a role in adipocyte inflammation as well as potentially account for the difference 
between visceral and subcutaneous adipose inflammation. 
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EXPERIMENTAL PROCEDURES 
 
Experimental animal care 
Cd14-/-, tlr4-/-, and myd88-/- mice have been backcrossed at least 12 generations to the 
C57BL/6J background.  Male C57Bl/6J mice were obtained from the Jackson Laboratory 
at 6-11 weeks of age.  Male ob/ob mice were obtained from the Jackson Laboratory at 4 
or 10 weeks of age.  All mice were housed (n=4 per cage) in ventilated polysulfone cages 
(Allentown Inc., Allentown, NJ) in a pathogen-free barrier facility maintained on a 12-
hour light / 12-hour dark cycle.  Mice had free access to autoclaved water and food.  
Obesity was induced by a high fat diet (HFD) consisting of ~60% of calories from fat 
(TD93075; Harlan Teklad, Madison, WI) starting at 11 weeks of age.  Prior to 11 weeks, 
mice were fed the standard pellet diet (LabDiet PicoLab 5053, Purina Mills, St. Louis, 
MO).  Control C57Bl/6J and ob/ob animals were maintained for their lifespan on 
standard diet in pellet or powder form.  Rosiglitazone treatment was initiated 2 weeks 
prior to sacrifice by grinding Avandia™ rosiglitazone maleate tablets (SmithKline 
Beecham Pharmaceuticals) into powered chow or softened HFD.  An effective dose of 
0.375 mg/day was calculated based on average food consumption of 5g/day/mouse.  
During the treatment period, control animals were fed diets in the same form.  Animal 
weight and food consumption was measured weekly for the duration of the experiment.  
Animal were fasted for 16-18 hours prior to sacrifice by cervical dislocation followed by 
bilateral pneumothorax.  All experiments employed male mice in accordance with the 
University of Massachusetts Medical School Institutional Animal Care and Use 
Committee (UMMS-IACUC). 
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Microarray gene expression and analysis 
Total RNA was extracted from isolated adipocytes (epididymal visceral, flank inguinal 
subcutaneous, 3T3-L1) of individual mice with a commercially available acid-phenol 
reagent (TRIzol; Invitrogen).  RNA concentration was assessed by absorbance 
spectroscopy and RNA integrity confirmed by nondenaturing agarose gel electrophoresis.  
Total RNA was used for the preparation of cRNA from primary fat cells for use with 
MG-U74v2 or MOE 430 GeneChips (Affymetrix).  RNA from primary fat cells was 
prepared from three groups of 2–4 mice for each condition.  Affymetrix protocols were 
followed for the preparation of cRNA from the mRNA or total RNA, which was 
hybridized according to Affymetrix instructions.  The GeneChips were washed with a 
GeneChip Fluidics Station 400 and were scanned with an HP GeneArrayScanner 
(Affymetrix).  Data analysis was performed from *.cel files in the MicroArray 
Computational Environment 2.0 (MACE 2.0; UMass Medical School, Worcester, MA).  
This procedure was performed by Leanne Wilson-Fritch, Sarah Nicoloro, Alison Burkart, 
and My Chouinard.  
 
Primary Adipocyte Isolation 
Perigonadal (epididymal in male mice) and subcutaneous (flank inguinal) fat pads were 
harvested in mice and placed immediately in Krebs-Ringer solution buffered with 
HEPES (KRH), pH 7.4, supplemented with 2.5% BSA.  Fat pads were cut into 0.3 cm3 
pieces and digested with freshly prepared collagenase type I (1mg/mL, 37°C; Clostridium 
histolyticum derived; Worthington Biochemical Corp) in previously prepared KRH, pH 
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7.4, 2.5% BSA – 2mL of collagenase solution was added per gram of tissue with a 
minimum of 5mL per container.  Samples were sealed with parafilm™ and digested 30-
45 minutes at 37°C in an orbital bath shaking at 100 rpm with ~2 cm excursion.  Digested 
samples were run through chiffon material to separate isolated cells from extracellular 
matrix, vasculature, and undigested tissue.  Adipocytes were separated by buoyancy and 
were washed 3 times in sterile PBS or KRH.  All materials were purchased sterile and 
pyrogen-free and all tools were autoclaved in sterile sleeves followed by UV irradiation.  
Clinical-grade water was used for reagent preparation. 
 
Ex Vivo Secretion Assay 
Isolated adipocytes were placed as a monolayer in 100μL of low-glucose DMEM (Gibco) 
supplemented with 2.5% LPS-free, free fatty acid poor BSA (lot pre-selected for lowest 
endotoxin concentration and no free fatty acids; Calbiochem).  Polymyxin B (5μg/mL; 
Sigma) was added to solution to inhibit endotoxin.  Adipocytes were incubated for 1-6 
hours at 37°C in an orbital bath shaking at 100 rpm.  Supernatant was removed and 
analyzed immediately or frozen at -20°C. 
 
ELISA 
Release of IL-6 from primary adipocytes was measured by ELISA, following the 
recommendations of the manufacturer (Pierce Endogen).  In brief, supernatants were 
obtained and diluted 1:10 prior to application to coated 96-well plates (2 hour, RT, orbital 
shaker – 600rpm, ~0.25 cm excursion).  Plates were washed with supplied detergent-
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based solution in automatic plate washer (3x, 300μL dispense, full aspiration) after 
sample addition, biotin-labeled antibody (1 hour, RT, orbital shaker – 600rpm, ~0.25 cm 
excursion), and streptavidin conjugated horse radish peroxidase (30 minutes, RT).  
Tetramethylbenzidine (TMB) solution (10-25 minutes, RT, light-protected) was used to 
visualize this colorimetric reaction and stopped with acidic solution prior to absorbance 
measurement at 450nm with subtraction of reference absorbance at 550nm (Safire 2, 
Tecan). 
 
Western blot analysis 
Cell extracts, equilibrated by total protein (10-25 μg total protein / lane), were separated 
by standard SDA-PAGE under reducing conditions and blotted to polyvinylidene 
difluoride membranes (PVDF; NEN Life Sciences) using a semidry blotting apparatus 
(0.8mA/cm2, 30-60 minutes; Thermo Scientific Owl).  Blots were blocked and first and 
second antibodies were diluted in 5% defatted dry milk/TBS/0.1% Tween 20.  After 1 
hour of incubation with respective primary antibody (CD14, 1:1000; Novocastra), blots 
were washed three times (TBS/0.1% Tween) and the secondary, peroxidase-conjugated 
goat anti-rabbit antibody (Promega) was added for an addition 1 hour.  Finally, blots were 
washed three times (TBS/0.1% Tween) and immunoreactive proteins were visualized 
using chemiluminescence (NEN Life Sciences).  Protocol previously described.186 
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Statistical Analysis 
Statistical analysis employed general linear mixed models, including analysis of variance 
(ANOVA) or Student’s t test followed by Bonferroni post hoc tests or statistically 
conservative Tukey/Kramer posthoc tests.  Statistics were performed using Prism 
Software (Graphpad, San Diego, CA), Statview 5.0.1 (SAS Institute, Cary, NC), or 
Sigma Plot 5.0 (SPSS, Inc., Chicago, IL).  Results are shown as mean±SEM unless 
otherwise stated.  A p-value of p<0.05 was regarded as a significant difference.  
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RESULTS & DISCUSSION 
 
Visceral adipocytes express more cytokines and chemokines than subcutaneous 
adipocytes in ob/ob mice 
Previous studies of adipose-derived inflammation employed varying sample 
techniques, including analysis of full adipose tissue as well as isolated adipocytes.  
Considering the recent discovery of macrophage infiltration into adipose tissue, which 
serves as a prominent source of inflammatory genes, we have analyzed only isolated 
adipocytes that were liberated from surrounding stroma, vasculature, and cell infiltrates.  
Given limited subcutaneous deposits in diet-induced obesity, we first employed the 
genetically obese ob/ob mouse, which has an inbred defect in the leptin gene, to 
interrogate whether differential cytokine and chemokine expression exist between 
visceral- and subcutaneous-derived isolated adipocytes.  Moreover, to investigate 
purported anti-inflammatory properties of the commonly employed type 2 diabetes 
medication rosiglitazone (thiazolidinedione class), we randomly stratified half our cohort 
to this treatment.  Using a normal chow diet (ND; 5% of calories derived from fat) in the 
genetic model of obesity, we compared the transcriptional profile in 4-week old ob/ob 
mice prior to development of overt diabetes; 26-week old ob/ob mice who were diabetic; 
and 26-week old ob/ob whom were fed rosiglitazone (6mg/ kg body weight/ day) for 2 
weeks prior to sacrifice (Figure 2.2). 
Utilizing analyses from the MicroArray Computational Environment (MACE) 
developed by our Diabetes and Endocrinology Research Center (DERC), we employed 
gene filters based on the MOE430-2 affymetric chip descriptions of biological function.  
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A filter comprised of 902 genes with known cytokine function demonstrated that 33% of 
these genes were increased in visceral adipocytes in comparison to subcutaneous 
adipocytes, while 5% of genes were decreased, and 33% were unaltered. (Figure 2.2)  
Similarly, a filter comprised of 326 genes with known chemokine function demonstrated 
that 32% of these genes were increased in visceral adipocytes in comparison to 
subcutaneous adipocytes, while 5% of genes were decreased, and 32% were unaltered. 
(Figure 2.3).  In light of the fact that macrophage infiltration and vascular components 
are prominent sources of inflammatory mediators, this transcriptional data from isolated 
adipocytes supports the theory that adipocytes themselves serve a role in determining 
depot-specific cytokine and chemokine expression.  
 
Toll-Like Receptor Pathway is involved in 3 models of adiposity 
Many cues can activate cascades that converge on similar inflammatory 
transcription factors, such as nuclear factor kappa B (NFκB), leading to similar 
chemokine and cytokine secretion.  In order to dissect out if distinct cues and pathways 
may be involved, we hypothesized that differences in inflammatory capacity between 
subcutaneous and visceral sources may parallel inflammatory changes in visceral 
adipocytes that occur before and after insulin resistance, which may be reflected with 
adipogenesis or in adipocytes in glucose impaired animals.  Employing a model of 
adipogenesis, namely 3T3-L1 adipocytes that form from fibroblast-like cells over 7 days, 
and two models of adiposity, high fat diet induced and genetic-induced, we interrogated 
transcriptional arrays for changes in pathways of genes according to the Kyoto 
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Figure 2.3:  Cytokine and Chemokine Expression Pattern in Visceral 
Adipocytes (Subcutaneous as reference)
Transcriptional profiles from ob/ob derived subcutaneous adipocytes and 
visceral adipocytes were compared.  The terms “cytokine” and “chemokine” 
were used to filter results from the Affymetrix gene chip.
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Encylopedia of Genes and Genomes (KEGG).  The Toll-Like Pathway was involved with 
a high degree of significance in all three pathways: 3T3-L1 differentiation, diet induced 
obesity, and genetic-induced obesity (Figure 2.4).  Within the Toll-Like Pathway and 
proximal to extracellular signaling events, CD14, the classical receptor for LPS, was 
modulated in these models of adipogenesis and adiposity.  Furthermore, previous 
transcriptional data in ob/ob mice revealed that CD14 was differentially expressed 
between subcutaneous and visceral adipocytes. 
 
Adipocyte CD14 transcript expression is enhanced in visceral depots in both genetic 
and diet-induced obesity with subsequent downregulation by rosiglitazone treatment 
In the ob/ob mouse, adipocyte expression of CD14 is upregulated from the 4-
week old non-diabetic mouse to the 26-week old overtly diabetic mouse with a 1.8-fold 
increase in subcutaneous adipocytes (p<0.05) and a 5-fold increase in visceral adipocytes 
(p<0.05) (Figure 2.5a).  Mice treated with rosiglitazone for 2 weeks prior to sacrifice 
demonstrated reduced CD14 expression in visceral adipocytes by 50% (p<0.05) and 
subcutaneous adipocytes by 50% (p<0.05) (Figure 2.5a).  In the diet-induced model, we 
see an 80% increase in visceral adipocyte CD14 expression with HFD feeding, which can 
be ameliorated with rosiglitazone treatment (p<0.05, p<0.05, respectively) (Figure 2.5b). 
 
Adipocyte CD14 protein expression is enhanced in visceral depots in ob/ob mice with 
subsequent downregulation by previous rosiglitazone treatment 
Following transcriptional clues, western blotting analysis confirmed greater CD14 
expression in ob/ob–derived visceral adipocytes over subcutaneous adipocytes (Figure 
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Figure 2.4: Kyoto Encylopedia of Genes and Genome (KEGG) Pathway Analysis
RNA microarrays were generated to compare different models of adiposity, including 
3T3-L1 adipocytes prior to (day 0) and following differentiation (day 6), high fat diet-
induced obesity in the C57BL/6J mouse, and genetic obesity in the ob/ob mouse.  
Algorithms from the Kyoto Encyclopedia of Genes and Genomes were applied to 
individual genes with a significant (p<0.05) change in absolute expression greater than 
1.2-fold.  The significance of the Toll-Like Receptor Pathway denotes the likelihood of 
the involvement of this pathway in their respective adiposity models, whereas 
annotated genes represent the genes in the Toll-Like Receptor Pathway involved in our 
comparison versus total genes believed to take part in this pathway. 
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Figure 2.5:  CD14 Transcriptional Profile  in Genetic and Diet-Induced Obesity
(a) Visceral (Visc) and subcutaneous (SQ) were isolated from 4 week old ob/ob 
(4wk), 26 week old ob/ob (26wk), and 26 week old ob/ob mice treated with 
rosiglitazone (26wk+R).  (b) Isolated visceral adipocytes were isolated from 
C57Bl/6J mice fed normal chow (NC) or high fat diet (HFD) without  (26wk) or with 
rosiglitazone (26wk+R).
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2.6).  As a control, increased collagenase digestion time, which could potentially cleave 
CD14 ectodomains during tissue digestion, showed no alteration in adipocyte CD14 
expression (Figure 2.6).  Moreover, short-term (2-week) treatment of rosiglitazone in 
animals prior to sacrifice was sufficient to reduce CD14 expression on ob/ob visceral 
adipocytes as demonstrated by western blot analysis (Figure 2.7).  Blots were re-probed 
for macrophage-specific proteins to control for potential macrophage contamination in 
our adipocyte preparations – no macrophage markers were visualized (Data not shown). 
 
Enhanced ex vivo IL-6 secretion from visceral adipocytes is diminished by in vivo 
rosiglitazone administration  
Following the hypothesis that CD14 may dictate adipocyte inflammatory 
potential, we investigated IL-6 secretion, a prominent adipocyte-derived inflammatory 
cytokine.  Following isolation, adipocytes secreted IL-6 in a time dependent manner, with 
over 4-fold accumulation of IL-6 in media at 6 hours in comparison to at 1 hour, which is 
consistent with previous reports (Figure 2.8).187  In contrast, adipocytes from flank 
subcutaneous depots secreted less IL-6 with accumulation at 6 hours similar to 
concentrations at 1 hour in visceral adipocytes (Figure 2.8).  In randomized ob/ob mice 
fed rosiglitazone 2 weeks prior to adipocyte isolation, we see a diminished ability of 
visceral adipocytes to secrete IL-6 ex vivo.  Therefore, rosiglitazone-mediated effects in 
vivo persisted in our ex vivo assay without direct addition of rosiglitazone (Figure 2.8).  
Therefore, our data suggest that depot-specific expression of CD14 as well as diminished 
CD14 expression in visceral adipocytes following rosiglitazone treatment correlate with 
functional IL-6 secretion ex vivo. 
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Figure 2.6:  Enhanced CD14 protein expression in visceral adipocytes from 
ob/ob mice
Isolated visceral (V) and subcutaneous (SQ) adipocytes from ob/ob mice.  Enhanced 
CD14 expression in visceral adipocytes was not effected by increased collagenase
digestion time.  β-actin controls provided.  Representative blot from 3 independent 
experiments.
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Figure 2.7:  Diminished visceral adipocyte CD14 protein expression in 
rosiglitazone-treated ob/ob mice
Isolated visceral adipocytes from 26-week old ob/ob mice (ob/ob) and 26-week old 
b/ b i t t d ith i lit f 2 k ( b/ b + R i) β ti t lo o m ce rea e  w  ros g azone or  wee s o o   os .  -ac n con ro s 
provided.  Representative blot from 3 independent experiments.
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Figure 2.8:  Enhanced ex vivo visceral IL-6 secretion diminished with 
rosiglitazone treatment
Isolated visceral and subcutaneous adipocytes from 26-week old ob/ob mice (-Rosi) 
d 26 k ld b/ b i t t d ith i lit f 2 k (+R i)an  -wee  o  o o m ce rea e  w  ros g azone or  wee s os  were 
incubated for 1, 3, or 6 hours in assay medium to assess IL-6 secretion.  Data 
presented as mean±s.e.m. (n=6 independent experiments).  *p<0.05, **p<0.01, 
***p<0.005 via student t-test in comparison to WT control. 
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LPS Signaling Disruption Abrogates Adipocyte IL-6 secretion   
To address previous data that differential CD14 expression corresponds with ex 
vivo IL-6 secretion, CD14-deficient (cd14-/-), TLR4-deficient (tlr4-/-), and MyD88-
deficient (myd88-/-) mice were stratified on to a normal diet (ND; 5% of calories derived 
from fat) and high fat diet (HFD; 60% of calories derived from fat) to determine if a 
functional LPS signaling complex played a role in: 1) adipocyte IL-6 secretion, 2) depot-
dependent adipocyte IL-6 secretion, and 3) diet-induced adipocyte IL-6 secretion (Figure 
2.2).   
In lean ND fed mice, visceral adipocytes continue to secrete IL-6; however, loss 
of CD14, TLR4, or MyD88 resulted in reduction of IL-6 secretion (Figure 2.9).  In HFD 
fed mice, we can appreciate a >4-fold increase in visceral adipocyte IL-6 secretion as 
would be expected in the obese, diabetic mouse versus the ND fed normoglycemic mouse 
(Figure 2.9).  However, again, loss of CD14, TLR4, or MyD88 resulted in attenuation of 
visceral adipocyte-derived IL-6 by 74%, 84%, and 50% respectively (Figure 2.9).  In 
contrast, subcutaneous adipocytes exhibit no statistical difference in IL-6 secretion in ND 
fed mice; however, this may be due to assay limitation as these cytokine concentrations 
were on the lower limit of detection (Figure 2.10).  With HFD treatment, there is an 
increase in subcutaneous-derived IL-6 expression, potentially revealing the prominent 
role of LPS signaling in permitting IL-6 secretion as subcutaneous adipocytes from HFD 
fed CD14, TLR4, and MyD88 secreted 91%, 50%, and 87% less IL-6 than control mice. 
(Figure 2.10)  Therefore, we see both a significant dietary effect on adipocyte IL-6 
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In comparison to WT on same diet:
* p<0.05 ** p<0.01
*** p<0.005 **** p< 0.001
Figure 2.9:  Loss of LPS signaling attenuates visceral adipocyte IL-6 expression 
Visceral adipocytes were isolated from C57Bl/6J (WT), cd14-/- (CD14-ko), tlr4-/-
(TLR4-ko), and myd88-/- (MyD88-ko) mice fed either normal diet (5% of calories 
f f t) hi h f t di t (60% f l i f f t) F hl i l t d di trom a  or g  a  e   o  ca or es rom a .  res y so a e  a pocy es
were incubated for 6 hours in assay medium to assess IL-6 secretion.  Data presented 
as mean±s.e.m. (n=6 independent experiments).  *p<0.05, **p<0.01, ***p<0.005, 
****p<0.001 via student t-test in comparison to WT control. 
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In comparison to WT on same diet:
* p<0.05 ** p<0.01
*** p<0.005 **** p< 0.001
Figure 2.10:  Loss of LPS signaling attenuates subcutaneous adipocyte IL-6 
expression 
Subcutaneous adipocytes were isolated from C57Bl/6J (WT), cd14-/- (CD14-ko), tlr4-
/ (TLR4 k ) d d88 / (M D88 k ) i f d ith l di t (5% f l i- - o , an  my - - y - o  m ce e  e er norma  e   o  ca or es 
from fat) or high fat diet (60% of calories from fat).  Freshly isolated adipocytes
were incubated for 6 hours in assay medium to assess IL-6 secretion.  Data presented 
as mean±s.e.m. (n=6 independent experiments).  *p<0.05, **p<0.01, ***p<0.005, 
****p<0.001 via student t-test in comparison to WT control. 
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secretion (2-way ANOVA, p<0.0001 in visceral, p<0.0001 in subcutaneous) as well as a 
significant genotype effect on adipocyte IL-6 secretion (2-way ANOVA, p<0.0001 in 
visceral, p<0.0001 in subcutaneous). 
Contrasting adipose depot sources taking into account all genotypes, there are 
significant depot and genotype effects in both ND (2-way ANOVA, p<0.005 depot, 
p<0.0001 genotype) and HFD fed mice (2-way ANOVA, p<0.001 depot, p<0.0001 
genotype).  However, looking at individual genotypes in depot-specific IL-6 secretion 
reveals a more complex story.   
In cd14-/- mice, there is diminished IL-6 secretion in both visceral and 
subcutaneous adipocytes in comparison to control mice regardless of diet, supporting the 
hypothesis that CD14 plays a role in adipocyte IL-6 production.  However, loss of CD14 
fails to normalize visceral and subcutaneous contributions of IL-6, suggesting that 
although the loss of CD14 in visceral adipocytes can decrease IL-6 secretion to a 
comparable or lower level than subcutaneous adipocytes in control mice, there are other 
pathways dictating higher IL-6 secretion in the cd14-/- visceral depot over subcutaneous 
depot.  Additionally, HFD treatment still leads to increased IL-6 secretion in cd14-/- mice, 
demonstrating that HFD maintains a pro-inflammatory effect independent of CD14. 
In tlr4-/- mice, there is diminished IL-6 secretion in both visceral and 
subcutaneous adipocytes in comparison to control mice regardless of diet, further 
supporting that LPS signaling plays a role in adipocyte IL-6 production.  However, in 
contrast to CD14, loss of TLR4 normalizes visceral and subcutaneous contributions of 
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IL-6 in ND fed animals, suggesting that either TLR4 plays an essential role in depot 
differences via either a more essential role in LPS signaling or in integration with other 
stimuli.  TLR4 has recently been implicated as a receptor for saturated, but not 
unsaturated, fatty acid-induced adipocyte inflammation, including the expression of IL-
6.188  Therefore, it is possible that integration of both LPS and saturated fatty acid stimuli 
can more fully account for depot-specific differences in inflammation, explaining why 
TLR4 is able to normalize depot inflammatory potential, while cd14-/- mice with TLR4 
expression maintain functional inflammatory contributions from saturated fatty acid 
stimuli.  On the other hand, HFD fed tlr4-/- mice show a paradoxical effect where 
subcutaneous adipocytes produce more IL-6 than visceral adipocytes.   Given that our 
HFD is predominantly composed of unsaturated fatty acids (~70% of fatty acid profile), 
this may suggest that visceral and subcutaneous adipocytes respond differently to 
unsaturated fatty acids in the tlr4-/- mice, which may be in part due to compensatory 
increases in TLR2 in tlr4-/- mice.189-191 
In myd88-/- mice, there is only diminished IL-6 secretion in visceral adipocytes in 
comparison to control mice regardless of diet.  However, of interest, there is no 
difference in IL-6 secretion in subcutaneous adipocytes in ND versus HFD fed mice, 
representing the only depot and genotype where IL-6 secretion does not respond to 
changes in diet.  Potential explanations for this phenomenon may be due to the essential 
role of MyD88 in IL-1 signaling pathways, which regulate adipogenesis.133,134  In accord 
with the hypothesis that proportional adipose expansion to accommodate lipid storage 
demands prevents alterations in homeostasis, it is possible that obesity and adipose 
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expansion that accompanies myd88-/- mice, as well as other mice with impeded IL-1 
signaling, allows partitioning of exogenous lipids without alteration in inflammation.  In 
contrast, enhanced visceral adipocyte IL-6 secretion with HFD treatment supports the 
belief that intrinsic differences between visceral and subcutaneous adipocytes exist, 
which may be exemplified by more consistent expansion of the subcutaneous versus 
visceral depot in IL-1 type 1 receptor knockout mice.133 
Addition of polymyxin B, which binds and sequesters LPS via electrostatic 
interactions, reduces IL-6 secretion in control and CD14-deficient visceral adipocytes, 
but not visceral adipocytes derived from tlr4-/- or myd88-/- mice (Figure 2.11).  Thus, 
implicating LPS as the pro-inflammatory stimulus in our ex vivo adipocyte assay system 
as well as further entertain the possibility of CD14-independent LPS signaling.  
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In comparison to Control Treatment:
* p<0.05 ** p<0.01   
*** p<0.005 **** p< 0.001
Figure 2.11:  Polymixin B treatment diminished ex vivo secretion of IL-6 in WT-
and cd14-/- – derived visceral adipocytes
Visceral adipocytes were isolated from C57Bl/6J (WT), cd14-/- (CD14-ko), tlr4-/-
(TLR4-ko), and myd88-/- (MyD88-ko) mice fed high fat diet (60% of calories from 
fat).  Freshly isolated adipocytes were incubated for 6 hours in assay medium 
without (Control) or with 5μg/ml Polymyxin B (+Polymyxin B) to assess IL-6 
secretion.  Data presented as mean±s.e.m. (n=6 independent experiments).  *p<0.05, 
**p<0.01, ***p<0.005, ****p<0.001 via student t-test in comparison to genotype-
matched untreated controls. 
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CONCLUDING THOUGHTS 
 
CD14 plays an essential role in adipocyte-derived IL-6 and may account for 
depot-specific inflammation in both models of genetic and diet induced obesity, 
representing a potential molecular target for the commonly employed type 2 diabetes 
medication rosiglitazone.  Although the anti-inflammatory effects of rosiglitazone are 
touted as a potentially beneficial property in combating cardiovascular disease, recent 
data suggests that rosiglitazone may have neutral, if not adverse, effects on mortality and 
cardiovascular events.192-200  This clinical correlate highlights the complexity of 
inflammation, suggesting that inflammation and their agents, i.e., cytokines, can not be 
simply considered equivalent to pathogenesis.  Although the acute phase reactant IL-6 is 
a classical marker of inflammation, it is a double-agent in metabolism subserving both 
beneficial and detrimental processes.  The detrimental role of IL-6 is suggested by 
population studies linking elevated serum IL-6 concentration and glucose intolerance 
with or without adjustment for obesity.80,81  Furthermore, addition of exogenous IL-6 has 
been shown in vivo and in vitro to impair insulin signaling components.96,97,123,201,202  
However, skeletal muscle produces IL-6 in response to exercise and temporally correlates 
with AMPK activation - a master switch to catabolic pathways that is involved in muscle-
contraction stimulated glucose uptake. 203-206  This potential beneficial role of IL-6 is 
supported by IL-6 infusion in human subjects that enhances glucose disposal and fatty 
acid oxidation.203  Conversely, global loss of IL-6 in il6-/- mice reduces AMPK activity in 
skeletal muscle and adipose at rest and diminishes absolute increases in response to 
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exercise.207  With advancing age, mice lacking IL-6 show impaired glucose tolerance, 
obesity, and dyslipidemia, suggesting that absolute deficiency of IL-6 may also be 
detrimental to systemic glucose homeostasis.207  Therefore, absence or excess of IL-6 
may be detrimental, suggesting a therapeutic level of IL-6 and likely tissue-specific 
benefits that underscores the importance of targeted therapeutics.  With emphasis on 
tissue specificity and local delivery strategies, our observation that LPS signaling 
components (CD14, TLR4, and MyD88) are involved in adipose cytokine elucidation and 
depot-specific inflammatory potential serves as a new approach in adjusting 
pathophysiological pathways to our own therapeutic goals. 
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SUMMARY 
 
Chronic low-grade inflammation has been suggested to perpetuate glucose 
intolerance and insulin resistance.  As a function of its potency and wide distribution, 
bacterial endotoxin or lipopolysaccharide (LPS) is a likely candidate to fuel chronic 
inflammation associated with diabetes.  To test this hypothesis, we employed mice 
deficient in components of the LPS signaling complex, namely CD14, TLR4 and 
MyD88, to investigate glucose homeostasis and insulin sensitivity following high fat diet 
challenge.  Contrary to our hypothesis, LPS signaling disruption impairs glucose 
tolerance and insulin sensitivity in cd14-/- and tlr4-/- mice without alteration in body mass 
or impairment of insulin secretion.  In contrast, high fat diet fed myd88-/- mice gained 
~20% more mass, but developed a mild glucose intolerance and insulin resistance.  In 
cd14-/- and tlr4-/-, but not myd88-/- mice, an exaggerated rebound phase in the insulin 
tolerance test was associated with enhanced catecholamine response to hypoglycemia, 
which could be abrogated by the adrenergic β-blocker propranolol.  The overlay of these 
mouse models reveals a divergence of phenotypes that demonstrate LPS signaling 
disruption may lead to glucose intolerance and insulin resistance in part due to enhanced 
sympathoadrenal tone, uncovering an essential role of innate immunity in physiological 
stress and its impact upon glucose homeostasis. 
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INTRODUCTION 
 
Glucose intolerance and insulin resistance are hallmarks of the type 2 diabetes 
population which is estimated to afflict 180 million people globally and anticipated to 
double by the year 2030.28  Despite a predominance of obesity in the type 2 diabetic 
patient population, it is estimated that the majority of obese individuals are not overtly 
diabetic, suggesting that nutrient excess alone is a strong but not singular risk factor for 
glucometabolic dysfunction.31,32  Recent studies over the last decade reveal chronic 
inflammation’s involvement in feeding behavior, activity, stress, insulin sensitivity, 
hypertension, truncal obesity, coagulation, and lipid metabolism – classical susceptibility 
factors in type 2 diabetes and hence potentially a common link in glucose intolerance and 
insulin resistance. 
We have previously shown that components of the LPS signaling pathway, 
namely CD14, TLR4, and MyD88, play a prominent role in adipocyte inflammation 
marked by its ability to produce IL-6 ex vivo.  Expression of the classical LPS receptor 
CD14 mirrors purported in vivo patterns of cytokine secretion with enhanced cytokine 
and chemokine secretion in visceral adipocytes, suggesting that it may play a role in the 
pathogenic potential ascribed to this adipose depot in clinical medicine.  Indeed, 
inflammatory responses to LPS stimulation is well documented in cell culture models, 
procedures eliciting acute insulin resistance in animals, and in clinical scenarios of severe 
infection that lead to sepsis with acute insulin resistance.  Therefore, LPS serves as an 
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attractive candidate for a causative factor in systemic inflammation and may play a role 
in fueling metabolic disturbance associated with type 2 diabetes. 
LPS binding to CD14 requires co-signaling partners MD2 and TLR4 to recruit 
either TIRAP/Mal to activate NFκB via MyD88 (MyD88-dependent pathway) or to 
recruit TRAM to activate IRF3 (MyD88-independent pathway).  LPS activates NFκB in 
multiple cell types, contributing to local and systemic elevation of inflammatory 
cytokines such as IL-6, TNFα, CRP, and MIF which have been associated with human 
diabetes.201  Moreover, randomly selected individuals in the Bruneck Study cohort 
demonstrated an association between subclinical endotoxemia > 50 pg/mL and carotid 
atherosclerosis, furthering an intriguing hypothesis that LPS may play a role in chronic 
inflammatory diseases.172  Given the importance of the MyD88-dependent pathway and 
NFκB in inflammation, we employed CD14-deficient (cd14-/-) and TLR4-deficient (tlr4-/-
) mice to block LPS binding and membrane signaling as well as MyD88-deficient 
(myd88-/-) mice to block the MyD88-dependent arm of LPS response in order to dissect 
their roles in glucose homeostasis and insulin sensitivity when challenged with high fat 
diet (HFD). 
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EXPERIMENTAL PROCEDURES 
 
Microarray gene expression and analysis 
Total RNA was extracted from isolated epididymal adipocytes or 3T3-L1 cells (ATCC, 
Manassas, VA) of individual mice with a commercially available acid-phenol reagent 
(TRIzol, Invitrogen Inc, Carlsbad, CA).  RNA concentration was assessed by absorbance 
spectroscopy and RNA integrity confirmed by non-denaturing agarose gel 
electrophoresis.  Preparation of cRNA, Affymetrix procedures, and data analysis via 
proprietary MicroArray Computational Environment 2.0 (MACE 2.0, Worcester, MA) 
were performed as previously described in Chapter II. 
 
Experimental animal care 
Cd14-/-, tlr4-/-, and myd88-/- mice have been backcrossed at least 12 generations to the 
C57BL/6J background.  C57Bl/6J mice were obtained from the Jackson Laboratory at 6-
11 weeks of age.  All mice were housed in ventilated polysulfone cages (Allentown Inc., 
Allentown, NJ) in a pathogen-free barrier facility maintained on a 12-hour light / 12-hour 
dark cycle.  Mice had free access to autoclaved water and food.  Obesity was induced by 
a high fat diet consisting of ~60% of calories from fat (TD93075; Harlan Teklad, 
Madison, WI) starting at 11 weeks of age.  Prior to 11 weeks, mice were fed the standard 
pellet diet (LabDiet PicoLab 5053, Purina Mills, St. Louis, MO).  Animal weight and 
food consumption was measured weekly for the duration of the experiment.  Animal were 
fasted for 16-18 hours prior to sacrifice by cervical dislocation followed by bilateral 
pneumothorax.  Harvested tissues were immediately frozen in liquid nitrogen and stored 
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at -80°C or fixed in formalin for chromagenic or immunohistochemical analysis.  All 
experiments employed male mice in accordance with the University of Massachusetts 
Medical School Institutional Animal Care and Use Committee (UMMS-IACUC). 
 
Activity Measurements 
Mouse movement was measured in custom-built activity monitors using 880 nm near-
infrared light emitting diodes with a scan frequency of 125 Hz and a minimum detection 
interval of 0.040 seconds (Appendix 1).  Ambulatory activity was calculated by 
sequential beam breaks, while stereotypic activity was calculated by multiple breaks of 
the same beam.  Mice were housed individually in their native cages in parallel with 
controls with an initial 24-hour acclimatization period and were monitored for at least 96 
hours. 
 
Body Fat Analysis 
Fat tissue, lean tissue, and free fluid were measured by time domain nuclear magnetic 
resonance (TD-NMR) using the Bruker LF50 (Bruker Optics Inc, Billerica, MA) which, 
in brief, utilizes relative relaxation amplitude and duration to provide tissue contrast. 
 
Analysis of metabolic parameters 
Metabolic testing (Glucose Tolerance Test and Insulin Tolerance Test) 
Glucose tolerance test was performed with intraperitoneal injection of 10% w/v D-
glucose in sterile water (2g glucose/kg body weight) following a 16-18 hour overnight 
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fast.  Whole blood glucose values were measured using Ascencia Breeze (Bayer 
Healthcare Diabetes Care Division, Tarrytown, NJ) or BD Logic (Becton, Dickinson and 
Co, Franklin Lakes, NJ) before and after 15, 30, 45, 60, 90, 120, 180, and 240 minutes 
post challenge/injection.  Insulin tolerance tests were similarly performed with i.p. 
injection of recombinant human insulin (0.75U insulin / kg body weight; Novolin R™, 
Novo Nordisk Inc, Princeton, NJ) and blood glucose measurements before and after 15, 
30, 45, 60, 90, 120, 180, and 240 minutes post challenge/injection.  Propranolol (2mg/kg 
body weight; Sigma, St. Louis, MO) or saline was injected 30 minutes prior to insulin 
tolerance test protocol initiation. 
 
Insulin-Induced Hypoglycemia and Norepinephrine measurement 
Hypoglycemia was induced in conjuction with insulin tolerance tests with i.p. injection of 
recombinant human insulin (1-1.5U insulin / kg body weight; Novolin R™, Novo 
Nordisk Inc, Princeton, NJ) and blood was collected in EDTA-treated capillary tubes 
(Sarstedt) before and after 45 and 90 minutes post injection. 
 
Norepinephrine was measured according to manufacturer’s protocol.  In short, plasma 
noradrenaline was extracted with a cis-diol affinity gel, acylated to N-acylnoradrenaline, 
converted enzymatically to N-acylnormetanephrine, and quantified in a competitive 
immunoassay (Alpco Diagnostics, Salem, NH).    
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Insulin 
Serum insulin was measured in the fed state or following a 14-16 hour fast using ELISA 
(Millipore, Billerica, MA) as previously described in Chapter II. 
 
Serum Lipid Analyses 
Serum was collected following 9 hour fast via retro-orbital bleeding.  Colorimetric 
analyses were employed to measure total cholesterol (Wako Diagnostics, Richmond, 
VA), triglyceride (Sigma, St. Louis, MO), and non-esterified fatty acid (Wako 
Diagnostics) according to manufacturer’s protocol. 
 
Adrenal Gland dissection and size analysis 
Ventro-medial adrenal surface was marked with surgical ink to maintain orientation.  
Adrenal glands were removed under a dissecting microscope with liberal margins to 
prevent tissue distortion and were immediately fixed in Bouin’s solution for 8 hours 
followed by a circulated wash overnight.  Tissue was embedded in paraffin and sliced in 
serial horizontal, longitudinal sections.  Images were captured with a Zeiss Axiovert 200 
inverted microscope (Thornwood, NY) and morphometric analyses were conducted by 
Axiovision 4.0.  Four largest sections by area were measured to approximate total size, 
while medullary area was measured and cortical area was calculated. 
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Statistical Analysis 
Statistical analysis employed general linear mixed models, including analysis of variance 
(ANOVA) or Student’s t test followed by Bonferroni post hoc tests or statistically 
conservative Tukey/Kramer posthoc tests.  Statistics were performed using Prism 
Software (Graphpad, San Diego, CA), Statview 5.0.1 (SAS Institute, Cary, NC), or 
Sigma Plot 5.0 (SPSS, Inc., Chicago, IL).  Results are shown as mean±SEM unless 
otherwise stated.  A p-value of p<0.05 was regarded as a significant difference.  
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RESULTS & DISCUSSION 
 
Models of adiposity implicate the Toll-Like Receptor Pathway 
To investigate inflammatory pathways involved in type 2 diabetes, we employed 
three models of insulin resistance, namely 3T3-L1 model of adipocyte differentiation, 
high fat diet-induced obesity, and genetic model of obesity in the ob/ob mouse.  Utilizing 
the Kyoto Encyclopedia of Genes and Genomes to analyze gene pathways altered, we 
identified the Toll-Like Receptor Pathway to be commonly involved with development of 
insulin resistance in 3T3-L1 adipogenesis (25 out of 201 annotated genes, p<2.66e-13), 
high fat diet-induced obesity (24 out of 201 annotated genes, p<6.85e-13), and genetic 
obesity (16 out of 201 annotated genes, p<1.03e-6) (Figure 2.4).  Comparison of these 
three models revealed similar expression patterns of CD14 and Toll-like receptor 4 
(TLR4) – classical cosignaling molecules responsible for LPS binding and 
transmembrane signaling. 
 
Progressive obesity in myd88-/-, but not cd14-/- and tlr4-/- mice 
Cd14-/- and tlr4-/- mice fed either normal diet (ND) or HFD gained weight at a 
similar rate to the C57Bl/6J control cohort (Figure 3.1a, b).  Myd88-/- mice on ND 
demonstrated a trend of weight gain but failed to meet consistent statistical significance; 
however, myd88-/- littermates fed HFD were 14% heavier at 6 months of age (40.5g  vs 
35.6g ; p<0.05) and 22% heavier at 12 months of age (50.9g vs 41.6g; p<0.05) (Figure 
3.1c).  NMR analysis of lean mass and adipose mass demonstrated no differences 
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Figure 3.1: Progressive obesity in myd88-deficient, but not cd14- and tlr4-
deficient animals
Growth curves of (a) cd14-/-, (b) tlr4-/-, (c) myd88-/- mice starting at 11 weeks of age 
when animals were randomized to normal diet (ND; black triangle) and high fat diet 
(HFD; black circle) cohorts.  Data presented as mean±s.e.m. (n=8 mice per group for 
weight analyses)
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between 12-month old cd14-/- and tlr4-/- mice from controls, while myd88-/- mice had 
enhanced adipose mass employing either ND (28.8±3.0% in myd88-/- vs 15.5±5.6%  in 
control mice; p<0.05) or HFD (42.1±1.7% in myd88-/- vs 29.4±4.2%  in control mice; 
p<0.05) (Figure 3.2a, b).  This data suggests that the majority of weight gain in myd88-/- 
mice is attributable to adipose mass, which may be due to the role of MyD88 in IL-1 and 
IL-18 signaling.  Previous studies demonstrated mature onset obesity in IL-1 receptor 
type I knockout mice, whereas unimpeded IL-1 signaling in IL-1 receptor antagonist 
knockout mice resulted in leaness.133,134  Furthermore, Netea et al. described obesity in 
mice with impaired IL-18 signaling due to either deletion of the IL-18 cytokine or the α-
chain of the IL-18 receptor.202  Therefore, this divergent phenotype on weight gain and 
adipose expansion may be in part due to the additional role of MyD88 in non-LPS 
signaling pathways, such as IL-1 and IL-18.    
 
Cd14-/-, tlr4-/-, and myd88-/-mice have no alteration in total ambulatory or circadian 
activity  
To assess energy expenditure, cd14-/-, tlr4-/-, and myd88-/- mice were individually 
housed in activity cages, demonstrating no differences in spontaneous ambulatory 
movements from age- and gender-matched controls (Figure 3.3a).  Alteration in 
circadian rhythm is a prominent source of metabolic variations when considering whole-
body knockouts; however, we observed no significant alteration in circadian activity 
patterns 203 (Figure 3.3b). 
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Figure 3.2: NMR-based Analysis of Lean Mass and Adipose Mass
(a) NMR analysis of absolute lean mass and (b) fat mass as a percentage of total dry 
mass.  Data presented as mean±s.e.m. (n=8).  *p<0.05, **p<0.01, ***p<0.005 via 
student t-test in comparison to WT control.
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Figure 3.3: Ambulatory Activity and Circadian Rhythm
(a) After 24-hour acclimatization, cd14-/-, tlr4-/- , and myd88-/- mice demonstrate 
similar overall ambulatory activity as approximated by sequential beam breaks in the            
x-y axis over a 72-hour period.  (b) Analysis of movement data demonstrated no 
alterations in circadian rhythm in comparison to WT mice.  Data presented as 
mean±s.e.m. (n=6 mice per group).  *p<0.05, **p<0.01, ***p<0.005 via student t-
test in comparison to WT control. 
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CD14 and TLR4 genotype impairs glucose tolerance and alters insulin response in 
middle-aged animals 
Despite the lack of genotype-specific changes in overall body composition in 
cd14-/- and tlr4-/- mice, glucose tolerance tests (GTT) uncovered glucose intolerance in 6-
month old mice fed either ND or HFD as demonstrated by greater peak glucose values 
that persists through later timepoints (Figure 3.4a).  However, myd88-/- mice 
demonstrated no alteration in glucose tolerance when fed ND as reported previously by 
Netea et al. (Figure 3.4a).202  Conversely, when challenged with HFD, myd88-/- reveals 
minor glucose intolerance shown at 120 minutes post-injection but fails to be significant 
to net glucose flux as assessed by area under the curve (AUC) (Figure 3.4a). 
In insulin tolerance tests, cd14-/- and tlr4-/- mice show no alteration in the initial 
downward phase in either ND- or HFD-fed cohorts, but unexpectedly rebound beyond 
baseline glucose in tlr4-/- mice, suggesting either impaired glucose uptake and/or 
inhibition of hepatic gluconeogenesis (Figure 3.4b).  On the other hand, myd88-/- mice 
display minimal insulin resistance in either ND or HFD fed cohorts (Figure 3.4b). 
 
Advanced-aged cd14-/- and tlr4-/- mice have marked glucose regardless of diet, whereas 
myd88-/- mice show minor HFD-specific effects 
To assess these phenotypes in the context of advancing age, which was necessary 
to uncover effects in IL-1 signaling knockouts, we followed these mice cohorts to 12 
months of age.  Similar to trends at 6 months of age, cd14-/- and tlr4-/- mice exhibited 
marked glucose intolerance fed either ND (AUC 49,191±3852 mg-min/dL in cd14-/- and 
AUC 46,423±2610 mg-min/dL in tlr4-/- vs AUC 29,256±1211 mg-min/dL in control 
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Normal Diet– 6 months High Fat Diet– 6 months
Figure 3.4: Glucose Homeostasis in Middle-Aged (6 month) cd14-/-, tlr4-/-, and 
myd88-/- mice
(a) Glucose tolerance test (GTT) of cd14-/-, tlr4-/-, and myd88-/- mice fed a normal diet 
(ND; left side) or high fat diet (HFD; right side). (b) Insulin tolerance test (ITT) of 
cd14-/-, tlr4-/-, and myd88-/- mice fed a normal diet (ND; left side) or high fat diet (HFD; 
right side)  Data presented as mean±s.e.m. (n=8 mice per group). 
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mice; p<0.0005, p<0.00005 respectively) or HFD (AUC 61,636±5318 mg-min/dL in 
cd14-/- and AUC 63,126±2335 mg-min/dL in tlr4-/- vs AUC 39,399±2129 mg-min/dL in 
control mice; p<0.001, p<0.00001 respectively) (Figure 3.5a).  Myd88-/- mice maintained 
glucose homeostasis when fed ND; however, HFD challenge uncovered glucose 
intolerance (AUC 57,626±2700 mg-min/dL in myd88-/- vs AUC 39,399±2129 mg-min/dL 
in control mice; p<0.00005) that was hinted at 6 months of age (Figure 3.5a). 
 
Enhanced glucose-induced insulin secretion in cd14-/-, tlr4-/-, and myd88-/- mice 
As insufficient insulin secretion and peripheral insulin resistance are two major 
origins of glucose intolerance, we first investigated whether glucose intolerance seen in 
these mice may be explained by a defect in insulin production.  Fasting insulin levels 
were 2-3-fold higher in myd88-/- mice with respect to control mice on the same diet; 
however, cd14-/- and tlr4-/- demonstrated no difference with controls on either ND or 
HFD (Table 3.1).  The secretion of insulin following an i.p. bolus of glucose (2g/kg body 
weight) demonstrated a time-weighted average of insulin in cd14-/-, tlr4-/-, and myd88-/- 
mice that exceeded that of wildtype controls (3213±344 ng-min/mL in cd14-/- ; 2598±325 
ng-min/mL in tlr4-/- ; and 5522±489 ng-min/mL in myd88-/- vs 1187±82 ng-min/mL in 
control mice; p<0.005, p<0.05, p<0.0005 respectively).  Although more insulin was being 
produced in cd14-/-, tlr4-/-, and myd88-/- mice, glucose intolerance may still arise from 
insulin resistance, specifically the inability of insulin to promote glucose uptake in 
peripheral tissues and/or inhibit hepatic gluconeogenesis and glycogenolysis. 
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aGTT GTT
Normal Diet – 12 months High Fat Diet– 12 months
b
ITT ITT
Normal Diet– 12 months High Fat Diet– 12 months
Figure 3.5: Glucose Homeostasis in Advanced-Aged (12 month) cd14-/-, tlr4-/-, 
and myd88-/- mice
(a) Glucose tolerance test (GTT) of cd14-/-, tlr4-/-, and myd88-/- mice fed a normal 
diet (ND; left side) or high fat diet (HFD; right side). (b) Insulin tolerance test (ITT) 
of cd14-/-, tlr4-/-, and myd88-/- mice fed a normal diet (ND; left side) or high fat diet 
(HFD; right side)  Data presented as mean±s.e.m. (n=8 mice per group).
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/ / /Table 3.1 Lipid Profile and Fasting Insulin of cd14- -, tlr4- -, and myd88- - mice
Cd14-/-, tlr4-/-, and myd88-/- at 52 weeks of age following 41 weeks of dietary
treatment demonstrated no genotype-specific lipid abnormalities with the exception
of reduced serum triglyceride in normal diet fed (ND) tlr4-/- mice (Ap<0.05) and
increased total cholesterol in high fat diet fed (HFD) myd88-/- mice (Bp<0.005).
Myd88-/- mice fed either a ND or HFD demonstrated elevated fasting serum insulin
(Cp<0.001). Values are expressed as mean ± s.e.m. NEFA, non-esterified fatty
acid.
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Enhanced hypoglycemic rebound in cd14-/- and tlr4-/- mice 
The ability of cd14-/-, tlr4-/-, and myd88-/- mice to respond to insulin was tested 
with an insulin tolerance test (ITT) that demonstrated no alteration in the initial 
downward phase in either ND- or HFD-fed cohorts, suggesting normal insulin sensitivity 
to an i.p. bolus of insulin (Figure 3.5b).  However, the rebound phase of the ITT was 
dramatic with cd14-/- and tlr4-/- mice fed ND exceeding basal glucose by 22% (p<0.005) 
and 25% (p<0.0001), respectively, at 180 minutes.  Whereas, HFD challenged cd14-/- and 
tlr4-/- mice surpassed basal glucose by 48% (p<0.0001) and 68% (p<0.0001), 
respectively, at 180 minutes (Figure 3.5b).  Whereas myd88-/- mice display minimal 
insulin resistance on ND, HFD-fed cohorts unmask impairment in glucose rebound after 
60 minutes in the 12-month old animals (Figure 3.5b).  The lack of insulin resistance or 
glucose intolerance in myd88-/- mice fed ND has been previously reported.202  Our data 
recapitulate this observation, but expose a minor glucose intolerance and insulin 
resistance in these mice when challenged by HFD.  Of note, the lack of changes in 
metabolism was unanticipated by both groups which hypothesized that loss of 
inflammatory players would dampen metabolic dysregulation.  Similar to the IL-18 
knockout mouse, frank obesity in myd88-/- mice was compensated with enhanced serum 
insulin in contrast to cd14-/- and tlr4-/- mice that show no alteration in fasting serum 
insulin (Table 3.1).  Paradoxically, cd14-/- and tlr4-/- mice demonstrate comparable 
cholesterol, triglyceride, and non-esterified fatty acid (NEFA) serum concentrations to 
control mouse cohorts despite marked glucose intolerance, whereas myd88-/- mice are 
hypercholesterolemic with normal triglyceride and NEFA with relatively minor 
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alterations in glucose homeostasis, supporting concepts that obesity and excess adipose 
by itself may not correlated to diabetes pathogenesis (Table 3.1).  In this spirit, we sought 
to investigate additional pathways that could impair glucose homeostasis in cd14-/- and 
tlr4-/- mice independent of adipose accumulation. 
 
Norepinephrine drives hypoglycemic rebound in cd14-/- and tlr4-/- mice 
Acute counter-regulatory pathways to hypoglycemia rely on adrenal-derived 
bioactive catecholamines to inhibit insulin secretion and peripheral glucose utilization, 
while promoting hepatic glycogenolysis and stimulate lipolysis.  The importance of the 
adrenal gland in glucose homeostasis is exemplified in human maladies where adrenal 
excess in Cushing’s disease is marked by hyperglycemia, whereas adrenal insufficiency 
in Addison’s disease is marked by hypoglycemia.  Secreted adrenal factors play an 
essential role of the hypothalamic-pituitary-adrenal (HPA) axis in stress reactivity, fat 
deposition, and hyperphagic responses, which may account for strain differences in 
rodents.211  Main contributions from the adrenal gland include: 1) corticosterone from the 
adrenal cortex that is involved in long-term glucose maintenance through 
gluconeogenesis and 2) catecholamines from the adrenal medulla that is essential for 
short-term glucose maintenance through glycogenolysis.  Mouse models of diabetes, such 
as the genetically obese ob/ob mouse, corroborate the contribution of adrenal glands as 
seen with normalization of insulin sensitivity and glucose uptake in adrenalectomized 
ob/ob mice in part due to normalization of hypothalamic melanocortin tone, 
corticosterone levels, and functional β-adrenergic signaling.212-218  Studies by 
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Zacharowski et al. found adrenal hypertrophy in tlr4-/- mice with functional implications 
in sepsis patients; however, did not address alterations in bioactive catecholamines in the 
context of glucose homeostastis.219  To determine if adrenal catecholamines may explain 
this rebound phase in the ITT, we measured norepinephrine at baseline, at 45 min post-
injection to coincide with the inflection in circulating glucose, and at 90 min post-
injection when basal glucose levels are re-established.  In cd14-/- mice, there is a 3.3- and 
2.5-fold increase in norepinephrine at 45 minutes and 90 minutes post-injection, 
respective to control mice (Figure 3.6a).  Similarly tlr4-/- mice show a 3.5- and 3.4-fold 
increase in norepinephrine at 45 minutes and 90 minutes post-injection, respective to 
control mice (Figure 3.6a).  In contrast, myd88-/- mice shows a norepinephrine response 
similar to control mice (Figure 3.6a).  Following the hypothesis that a hyperactive 
adrenal response to hypoglycemia may account for this alteration in glucose homeostasis, 
we preconditioned mice with the non-specific β-blocker propranolol prior to insulin 
administration.  Sham saline injection prior to insulin-induced hypoglycemia 
recapitulated enhanced glucose flux previously demonstrated in cd14-/- (AUC 
39,205±1092 mg-min/dL in cd14-/- vs AUC 31,188±964 mg-min/dL in control mice; 
p<0.002) and tlr4-/- mice (AUC 41,276±1827 mg-min/dL in tlr4-/- vs AUC 31,291±1070 
mg-min/dL in control mice; p<0.0001) (Figure 3.6b,c).  Indeed, pretreatment with 
propranolol mitigated this excess flux in both cd14-/- and tlr4-/- mice (p<0.005, p<0.0005, 
respectively) (Figure 3.6b,c).  
 
Expansion of total and medullary adrenal size in tlr4-/- and myd88-/- mice 
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p<0.0001 p<0.0005p<0.002 p<0.005
b
Figure 3.6: Norepinephrine drives hypoglycemic rebound in cd14-/- and tlr4-/-      
mice 
(a)  Cd14-/- and tlr4-/- mice were injected i.p. with insulin (1-1.5U / kg body weight) 
to elicit a counter-regulatory norepinephrine response to hypoglycemia.  Blood was 
taken before and after 45 and 90 minutes for norepinephrine measurements.  
Propranolol (2mg/kg of body weight) or saline was injected 30 minutes prior to 
insulin tolerance tests to demonstrate the role of β-adrenergic blockade on glucose 
flux, represented as area under the curve (AUC), in (b) cd14-/- and (c) tlr4-/- mice.  
Data presented as mean±s.e.m (n=8). 
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Adrenal gland dissection revealed increased overall, calculated cortical, and 
medullary size in tlr4-/- and myd88-/- mice (Figure 3.7).  Cd14-/- mice fit a trend of 
medullary expansion, the adrenal region responsible for catecholamine synthesis, but 
failed to meet statistical significance (Figure 3.7).  Of interest, strain analysis by Jackson 
Laboratories demonstrate that male C57Bl/6J mice demonstrate 100% more adrenal mass 
than gender-matched sv129 mice and 40% more than strain-matched female 
littermates.220,221  In fact, adrenal mass in C57Bl/6J mice is considered exceptional in 
comparison to 13 other common strains of mice with greater than 2.5 standard deviations 
above mean adrenal mass.220,221  Coupled with our data demonstrating excess adrenal 
counter-regulation to hypoglycemia in male mice, this gender-specific difference in 
adrenal physiology may partially explain the lack of insulin sensitization seen in male 
mice by Shi et al. in contrast to their female littermates.  Moreover, additional 
impairment of glucose tolerance and insulin sensitivity in our studies may be attributed to 
further backcrossing (12+) into the C57Bl/6J background, potentially allowing more 
complete penetration of the adrenal contribution, which appears to be an “exceptional” 
characteristic of the C57Bl/6J background. 
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In comparison to WT
* p<0.05
** p<0.01
*** p<0.005
**** p< 0.001  
****
Figure 3.7: Adrenal Gland Size Analysis
Four largest sections by area (horizontal longitudinal) were measured to     ,     
approximate total size, while medullary area was measured and cortical area was 
calculated.  Images quantification were conducted by Axiovision 4.0 at1.5x 
magnification. Data analyzed with a 1-way ANOVA with Dunnet Post-Hoc Test with 
a p<0.05 considered significant.  Data presented as mean±s.e.m (n=5-6). 
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CONCLUDING THOUGHTS 
 
Despite data suggesting insulin sensitization in the C2C12 skeletal muscle model 
with TLR4 abrogation in vitro and insulin resistance of the 3T3-L1 adipocyte cell model 
with TLR4 activation in vitro, human population studies of TLR4 and CD14 
polymorphisms have failed to demonstrate a clear association between functional changes 
in LPS response and predisposition to diabetes or metabolic syndrome.222-232  
Furthermore, human serum studies of soluble CD14 (sCD14) show a positive correlation 
with insulin sensitivity, supporting our observation that whole body loss of CD14 may 
lead to insulin resistance.233  In concert with previous experimental and population 
studies, our data support a hypothesis that whole body alteration of LPS signaling may 
involve glucose homeostasis beyond insulin-sensitive peripheral tissues and hence 
systemic therapeutic strategies to attenuate LPS signaling may have unclear benefits in 
glucose lowering.   
The novel employment of three genetic knockouts, namely cd14-/- , tlr4-/-, and 
myd88-/-, localizes metabolic observations to these genes shared role in LPS signaling in 
lieu of alternate biological functions.  The overlay of these mouse models suggests an 
intimate association of CD14 and TLR4 with sympathoadrenal tone and impaired glucose 
homeostasis.  While, less severe metabolic disturbance in the MyD88 mouse, even in the 
context of augmented obesity, suggests the importance of MyD88 in non-LPS pathways 
and supports the hypothesis that obesity alone is not a singular cofactor for glucose 
intolerance and insulin resistance. 
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  Our results further support that multiple etiologies are involved in 
glucometabolic derangements and invites inquiry into the role that multiple organs play 
in the pathogenesis of glucose intolerance and insulin resistance.  Moreover, these data 
demonstrate that whole body disruption of LPS signaling, despite its potential anti-
inflammatory sequellae, leads to metabolic derangement and thus tissue-specific effects 
must be carefully considered with the development of future therapeutic strategies. 
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Discussion and 
Final Thoughts 
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DISCUSSION 
 
CHAPTER II 
  
Differential expression of CD14 between visceral and subcutaneous depots 
coupled with the prominent role CD14, TLR4, and MyD88 plays in ex vivo IL-6 secretion 
provides an attractive explanation for depot-specific inflammatory potential.  Moreover, 
the CD14 ligand LPS is an omnipresent pro-inflammatory stimulus in the human body 
with well-established pro-inflammatory functions that might contribute to insulin 
resistance.  Indeed, bacterial-derived LPS can drive sepsis (also classified as the systemic 
inflammatory response syndrome (SIRS) of infectious origin), promoting inflammatory 
cascades that culminate in a “cytokine storm.”  Of interest, hyperglycemia is seen in 
many septic patients, but diabetic patients are particularly predisposed, which would 
match our observations that CD14 transcriptional expression increases in both genetic 
and diet-induced models of obesity with concurrent diabetes.  Our observation of 
enhanced CD14 expression in visceral adipocytes has recently been validated by Poulain-
Godefrey et al. who took paired adipose tissue biopsies from omental (visceral type) and 
subcutaneous depots.222  Although the pattern of enhanced omental expression of CD14 
persisted in all volunteers, this was independent of obesity as well as glycemic state.222 
 Preferential CD14 expression in visceral adipocytes may be sufficient to account 
for the pro-inflammatory potential of this depot; however, as predicted by receptor-ligand 
kinetics, the availability of the LPS stimulus may also be responsible.  Although LPS can 
be found in circulating blood, the majority of the body’s LPS is likely associated with 
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bacterial populations.  In particular, it is popular belief that bacterial populations that co-
exist with gut mucosa numerically outnumber the cells of the human body; thus, 
representing a significant reservoir of LPS.  Disruption of the integrity of the 
gastrointestinal tract may leach LPS into the peritoneum, fueling chronic inflammation 
or, depending on the severity, initiate acute sepsis.  Moreover, chronic gastrointestinal 
inflammation may also uniquely contribute, as a function of anatomy, multiple 
inflammatory stimuli to visceral, but not subcutaneous adipose.  Indeed, diverticulitis has 
been associated both with obesity and diabetes as well as radiologic findings termed “fat 
stranding” that commonly represent active infection or inflammation of adipose 
tissues.223,224  Additionally, the gastrointestinal system from the lower esophagus to upper 
anal canal drain into the hepatic portal venous system, which shares drainage with 
visceral adipose, but not subcutaneous adipose; thus, by proximity, may alter LPS 
bioavailability.  Therefore, anatomic juxtaposition of visceral adipose with the major 
reservoir of LPS in the gastrointestinal tract may play a pathophysiological role in 
visceral adipose inflammation and supports our observation of attenuated IL-6 secretion 
from visceral adipocytes isolated from mice deficient in the LPS signaling pathway, i.e., 
CD14, TLR4, and MyD88. 
 Though differential expression of CD14 and varying exposure of LPS may 
contribute to depot-specific inflammation, what accounts for enhanced subcutaneous and 
visceral adipocyte IL-6 secretion in WT mice fed a high fat diet?  Likewise, how can this 
dietary effect be attenuated by the loss of CD14, TLR4, and MyD88?  Studies by Cani et 
al. has promoted a theory of metabolic endotoxemia with the posit that HFD feeding: 1) 
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enhances intestinal permeability with downregulation of genes encoding tight junction 
proteins, and 2) skew bacterial populations in the gut mucosa to LPS-containing species; 
therefore, leading to acute elevation of circulating LPS that was sustainable by continued 
high fat dietary intake.225,226  Correlates in humans are preliminary with one study 
demonstrating that in apparently healthy men, 3-day food diaries reveal a positive 
association of serum LPS levels with fat intake; however, total energy intake was yet a 
better predictor of LPS levels.227 
Our data demonstrates for the first time both differential expression of CD14 
between visceral and subcutaneous adipose depots as well as the central importance of 
members of the LPS signaling cascade (CD14, TLR4, MyD88) in mediating depot-
specific and high fat diet-induced adipocyte inflammation.  With anatomic susceptibility 
to LPS exposure, visceral adipose is predisposed to a prominent inflammatory cue that is 
mediated by the LPS signaling cascade.  Early evidence that high fat diet may elevate 
circulating LPS levels lends credence to our observation that LPS signaling disruption 
can mitigate HFD-induced adipocyte inflammation.  Enhanced expression of 
inflammatory cytokines by visceral, but not subcutaneous, adipocytes drains directly into 
the portal circulation where it may have direct impacts on hepatic contributions to 
systemic inflammation and metabolism.228  Therefore, enhanced CD14 expression on 
visceral adipocytes integrates both inputs of inflammatory stimuli with outputs to 
relevant target organs, providing explanation for enhanced inflammatory potential of the 
visceral depot as well as afford new strategies for therapeutic interventions. 
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CHAPTER 3 
 
We present for the first time that whole-body LPS signaling disruption in CD14- 
or TLR4-deficient mice leads to marked impairment of glucose tolerance and insulin 
sensitivity with an enhanced norepinephrine counter-regulatory response to insulin-
induced hypoglycemia.  We have previously shown that loss of CD14 and TLR4 limits 
production of IL-6 from visceral and subcutaneous adipocytes; thus, attenuating depot-
specific and high fat diet induced inflammation.  Following the hypothesis that 
inflammation drives metabolic dysfunction with glucose intolerance and insulin 
resistance, we expected that CD14- and TLR4-deficient mice with demonstrated 
reduction in ex vivo IL-6 secretion capability would improve glucose homeostasis.  
However, our surprising result of impaired glucose homeostasis in these mice contradicts 
our hypothesis, yet elucidates the importance of global LPS signaling in glucose 
homeostasis and point to new avenues of inquiry. 
The role of CD14 in organisms can serve both pro- and anti-inflammatory 
functions.  In addition to membrane bound forms, CD14 can be released as a soluble 
protein, typically from the liver, that circulates throughout the vasculature.  Soluble 
CD14 (sCD14) can confer LPS sensitivity to cells that do not normally express CD14, 
such as endothelial cells.  Therefore, sCD14 enhances the pool of LPS-sensitive cell 
populations, increasing sources of cytokine release, which may be seen generally as pro-
inflammatory.  However, free sCD14 maintains its ability to bind and sequester LPS in 
the circulation.  LPS-sCD14 complexes are able to donate LPS molecules to high density 
lipoproteins (HDL) via a reaction catalyzed by LPS binding protein (LBP).  It is 
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estimated that sCD14 amplifies transfer of LPS to HDL by 30-fold, resulting in LPS-
laden HDL that can be transported to the liver for elimination.229  Therefore, sCD14 is a 
double agent - expanding the population of LPS-sensitive cells as well as sequestering 
and targeting circulating LPS for elimination.157,230 
With elimination of both sCD14 as well as membrane-bound (mCD14) in CD14-
deficient mice, it is unclear whether a net anti-inflammatory effect prevails.  In accord, it 
is difficult to ascertain the relationship of inflammation with whole body glucose 
homeostasis in these mice.  In our adipocyte studies, it is clear that loss of membrane-
bound (mCD14) function results in attenuated IL-6 secretion.  However, with an 
appreciation of various target cells and organs that LPS may affect, an isolated metabolic 
phenotype would be surprising.  Nonetheless, population data in insulin-resistant 
individuals suggests that serum sCD14 is inversely correlated with fasting insulin – a 
surrogate for insulin resistance.  Therefore, this data suggests that on the complexity level 
of an organism, it appears that greater sCD14 concentration is associated with improved 
whole-body insulin sensitivity.  This association, though opposite of our experimental 
animal setup, lends support to a hypothesis that global loss of CD14 may impair insulin 
sensitivity, inviting future inquiries in the importance of CD14 function in other organs 
that may shape whole body metabolism.  
The adrenal gland is one such example of an organ that may not be a classical 
insulin-sensitive tissue, but maintains LPS as a potential input and mediates whole body 
glucose homeostasis as an output.  In fact, adrenalectomy in genetically obese ob/ob mice 
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is sufficient to improve hyperglycemia, weight gain, and insulin-induced glucose 
uptake.204-206,231-233  Adrenalectomy in insulin-resistant lipoatrophic mice corrects hepatic 
insulin resistance and enhances muscle glucose uptake, highlighting the contribution of 
adrenal glands to tissue-specific as well as systemic glucose homeostasis.234 
Our data is the first to demonstrate that CD14- and TLR4-deficient mice have an 
enhanced adrenal counter-regulatory response to hypoglycemia – marked by a dramatic 
increase in the bioactive catecholamine norepinephrine.  Consistent with compensatory 
adrenal hypertrophy seen in previous studies of TLR4-deficient mice, our studies 
demonstrate adrenal hypertrophy in both CD14- and TLR4-deficient mice.207  Excess 
norepinephrine can direct many metabolic factors, including lipolysis, insulin secretion, 
glucagon secretion, glucose uptake, and hepatic glucose production.235  It is possible to 
speculate that excess norepinephrine may mimic pheochromocytoma, which is a 
neuroendocrine tumor of the adrenal medulla marked by excess production of bioactive 
catecholamines.  In this malady, excess norepinephrine contributes to insulin resistance 
and hyperglycemia, stemming from increased lipolysis, gluconeogenesis, and 
glycogenolysis.236-238  The role of catecholamine-driven counter-regulatory responses in 
physiological glucose maintenance provides a basis for pathophysiological metabolic 
changes with alteration in norepinephrine regulation that is seen in our CD14- and TLR4-
deficient mice. 
It is important to note that adrenal medullary catecholamine secretion is a salient 
response to reduced glucose availability to the brain, initiating a hyperglycemic response 
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aimed at restoring glucose supply – the preferential energy source for cells of the central 
nervous system.239  Local destruction of spinally-projecting norepinephrine and 
epinephrine neurons abrogates the hyperglycemic response, suggesting that adrenal 
secretion is both centrally controlled and essential for elevation of systemic glucose.239  
In addition to reduced glucose supply to the brain, LPS is a prominent stimulus during 
septic shock, elevating adrenal catecholamines to lower insulin and enhance glucose 
production – processes interrupted by either adrenal demedullation or guanethidine-
induced sympathectomy.240  Hence, both hypoglycemia and LPS employ central 
mechanisms to release catecholamines in order to elevate glucose availability.  Therefore, 
it remains possible that exaggerated norepinephrine response to hypoglycemia seen in our 
CD14- and TLR4-deficient mice may be due to central defects; in particular as 
brain/neuron insulin receptor specific knockout (NIRKO) mice show diminished 
norepinephrine responses to insulin-induced hypoglycemia; thus, localizing these 
responses to central pathways.241 
As CD14 has additional functions outside LPS signaling (i.e., LPS sequestration 
and elimination), so is TLR4 purported to mediate other inflammatory signals, such as 
saturated, but not unsaturated, free fatty acids – an intriguing hypothesis that validates the 
danger of high saturated fat consumption in the western diet.  However, in our in vitro 
studies performed by Melvin Chan, application of the commonly employed saturated free 
fatty acid palmitate had no stimulatory effect on IL-6 secretion in macrophage or 
microglial cells (Appendix 2).  In contrast, IL-6 secretion was observed with activation 
of both the LPS signaling pathway (CD14/TLR4/MyD88) and the Poly I:C pathway 
116
  
(TLR2) (Appendix 2).  In accord, macrophages and microglial cells derived from TLR2-
deficient animals lost responsiveness to Poly I:C, while cells derived from CD14-, TLR4-
, or MyD88-deficient animals lost responsiveness to LPS (Appendix 2).  As proper 
solubilization of free fatty acids in aqueous solutions is challenging, free fatty acid 
concentration was validated with commercial colorimetric assays, while free fatty acid 
availability to cells was validated with enhanced oxygen consumption (Appendix 3).  It 
is important to note that careful reagent selection is paramount in these studies as 
acceptable endotoxin levels in bovine serum albumin (BSA) and fetal bovine serum 
(FBS) routinely used in cell culture maintenance are sufficient for inflammatory 
activation of these cell types.  Although our data do not support saturated free fatty acid 
signaling through TLR4, we must assume that differences in cytokine production with 
saturated and unsaturated free fatty acids persist in the context of similar levels of LPS 
contamination from reagents.  Thus, this suggests that saturated free fatty acids may yet 
potentiate LPS-driven inflammation through the CD14-TLR4 signaling complex, 
potentially taking advantage of the role of CD14 in phospholipid and LPS cellular 
influx.242-246 
It is clear from molecular and nutritional studies that not all fatty acids are created 
equal; hence, high fat diet selection based on fatty acid profile rather than total calories 
from fat should be considered.  In both our studies, we utilize a diet with a predominance 
of cis unsaturated and polyunsaturated fatty acids (~68% of total fatty acids) in line with 
a relative fatty acid profile recommended by the USDA Dietary Reference Intake (DRI) 
guidelines.247  Furthermore, based on results from the Continuing Survey of Food Intakes 
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by Individuals (CSFII), ~34% of fat calories consumed by individuals in the United 
States are derived from saturated fat in contrast to previous mouse studies employing 
diets with an unrealistic predominance of saturated fatty acids (>90%).188,247  In order to 
achieve diets with high saturated fatty acid content, animal sources such as lard, are 
typically employed.  In conversations with industry researchers supplying fats and oils 
for food manufacture, it is a common belief that animal sources have higher levels of 
bacteria and bacterial products than vegetable sources.  Although in line with government 
bacteria/endotoxin standards, this provides a significant confounding effect in LPS-
related research in animals.  Therefore, we must take into account that diets rich in 
saturated fat may employ animal-based fat sources that could represent higher exogenous 
sources of LPS/endotoxin.  This difference may be reflected in personal communications 
that suggest that lard-based diets induce glucose intolerance faster in C57Bl/6J mice.   
Higher exogenous LPS in saturated fat based diets may explain why Shi et al. 
failed to see changes in glucose tolerance in his male mice.  With HFD harboring LPS, 
HFD fed control mice should become glucose intolerant and insulin resistant.  However, 
TLR4-deficient mice should be protected from this HFD/LPS effect, suggesting either a 
relative improvement in glucose homeostasis or masking of genotype-specific glucose 
intolerance as suggested by our studies.188  This comparison may be further exaggerated 
by saturated free fatty acid signaling through TLR4.  In sum, this may yet have important 
implications for one’s food selection, but the proper correlate should employ more 
realistic free fatty acid profiles.  
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As discussed previously in Chapter III, there was improvement in insulin 
sensitivity in female TLR4-deficient mice; however, this again may be due to high LPS 
contamination in diets.  However, a relative gender effect persists and may be explained 
by gender differences in adrenal mass.  The male C57Bl/6J mouse has enhanced adrenal 
mass in comparison to female C57Bl/6J, male sv129, and female sv129 mice.208,209  With 
our results suggesting altered homeostasis with adrenal excess, we may speculate that 
female mice may rely less on adrenal contributions.  Furthermore, reduced adrenal mass 
in the sv129 background may be a confounder, suggesting that knockout mice be more 
extensively backcrossed on to the C57Bl6/J background.  In fact, well documented sexual 
dimorphism in neuroendocrine and inflammatory signaling supports our hypothesis that 
the intersection of adrenal and LPS signaling pathways with glucose homeostasis 
provides a strong basis for gender-specific and strain-specific differences in metabolic 
phenotypes.248  
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FINAL THOUGHTS 
 
Recent data from the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) and the Action in Diabetes and Vascular Disease: Preterex and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) studies suggest that intensive 
reduction of glucose (glycated hemoglobin < 6.0% and 6.5%, respectively) failed to 
reduce major macrovascular events (death from cardiovascular causes, nonfatal 
myocardial infarction, or nonfatal stroke).249,250  As the majority of our diabetes patients 
will eventually succumb to macrovascular complications, this data underscores the need 
to understand how diabetes beyond hyperglycemia contributes to atherosclerosis and 
vascular dysfunction.  Moreover, emerging data in countries with the highest rate of 
diabetes development, namely India and China, suggest that ethnic differences in insulin 
secretion and inflammatory contribution predispose even lean individuals in these 
populations, calling for a high degree of clinical suspicion as these countries adopt 
western dietary practices.251-256  In the United States, October 2007 marked the first of the 
estimated 78 million baby boomers to be qualified for social security, representing the 
aging of our population and calling for an expansion of our therapeutic armamentarium.  
Therefore, as the global burden of diabetes, obesity, and their concomitant macrovascular 
sequellae intensifies, multiple avenues of therapy must be investigated.  
Further understanding and dissection of the complex crosstalk between 
parenchymal cells, vascular cells, circulating cells, and the central nervous system will 
continue to represent a challenge in this orchestra of interactions, but also ensures that 
120
  
scientific inquiry no matter how narrowly defined contributes to our base of knowledge 
and is readily applicable to multiple fields.  The complex interplay of the human body 
also serves as opportunities where properly targeted therapeutic strategies will one day be 
able to modify human disease and we can truly go from bench to bedside.  It is always 
with the small pebble in a pond that science is both daunting and exhilarating, questions 
multiply faster than answers, and a thesis is never finished. 
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Supplement 
Cells of the Vasculature – Lessons from Atherosclerosis 
 
Using atherosclerosis as a framework to discuss vascular inflammation and injury, 
we will draw on mechanisms of vascular dysfunction with immune cell chemotaxis to 
explain likely correlates with the vasculature of insulin-sensitive peripheral tissues.  In 
brief, the antiquated view of atherosclerosis as a gradual process of lipid accumulation is 
no longer favored.  In lieu, atherosclerosis is seen as an active cellular process that may 
progress to form advanced plaques, which are composed of a highly thrombotic core 
shielded by a fibrous cap, hence protecting the circulation from acute thrombotic events 
(Supplement, Figure 1).  This degree of plaque formation is not currently believed to 
take place in the larger vessels supplying insulin-sensitive peripheral tissues, but the 
principle of vascular dysfunction leading to endothelial damage, increase in cellular 
adhesion molecules, and ensuing recruitment of leukocytes are emerging concepts in 
adipose inflammation  
 
Normal Arterial Wall 
Far from an inert conduit, the living arterial wall hosts dynamic interchange 
between its cellular residents, most importantly endothelial cells, vascular smooth muscle 
cells, and their surrounding extracellular matrix (Supplement, Figure 1 inset).  
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From Young JL, Libby P.  Atherosclerosis.  Chapter in: Lilly LS, editor.  
Pathophysiology of Heart Disease, 4th edition.  Philadelphia: Lippincott Williams 
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Supplement, Figure 1: The Vascular Wall
The arterial wall consists of three layers (Fig. 1.12, inset): the intima, closest to 
the arterial lumen and therefore most “intimate” with the blood; the media,
which is the middle layer; and the outer adventitia. The intima consists of a 
single layer of endothelial cells that acts as a metabolically active barrier            
between circulating blood and the vessel.  The media is the thickest layer of the 
normal arterial wall. Boundaries of elastin, known as the internal and external 
elastic laminae, separate this middle layer from the intima and adventitia, 
respectively.  The media, composed of smooth muscle cells and extracellular 
matrix, subserves the contractile and elastic functions of the vessel.  The 
adventitia, the outer lining of the artery, contains the nerves, lymphatics, and 
blood vessels (vasa vasorum) that nourish the cells of the arterial wall.
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Understanding the dysfunction that leads to disease requires knowledge of the normal 
function of these components. 
 
Endothelial Cells 
In a healthy artery, the endothelium serves structural, metabolic, and signaling 
functions that maintain the homeostasis of the vessel wall.  The tightly adjoined 
endothelial cells form a barrier that contains circulating blood within the lumen of the 
vessel and limits the passage of large molecules from the circulation into the 
subendothelial space.   
The endothelium expresses cell-surface and circulating antithrombotic molecules 
(e.g., heparan sulfate, thrombomodulin, and plasminogen activators, prostacyclin and 
nitric oxide [NO]), favoring a net anticoagulant state; however, the endothelium can also 
produce prothrombotic molecules when stressed (see below). 
Endothelial cells in post-capillary venules respond to local injury or infection by 
secreting immune cell recruiting chemicals known as chemokines, while enhancing 
expression of cell-surface adhesion molecules that serve to anchor mononuclear cells to 
the endothelium and facilitate migration to the site of tissue injury.  In the absence of 
such pathologic stimulation, healthy arterial endothelial cells resist leukocyte adhesion.  
However, under adverse influences, endothelial cells actually recruit leukocytes to the 
vessel wall.  In sum, the normal endothelial layer provides a protective non-thrombogenic 
surface with homeostatic vasodilator and anti-inflammatory properties (Figure 1.12A). 
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Vascular Smooth Muscle Cells 
Smooth muscle cells within the vessel wall is best known for their contractile 
function, responding to various vasoactive substance derived from circulating agents, 
nerve terminals, or overlying endothelium.  However, vascular smooth muscle cells also 
synthesize the collagen, elastin, and proteoglycans that form the vascular extracellular 
matrix (Figure 1.12A).  Similar to a normal injury response (e.g. scar formation), the 
synthetic functions of smooth muscle cells become more prominent and may contribute 
to its pathogenesis as will be outline below in the Activated Arterial Wall . 
 
Activated Arterial Wall 
As the normal arterial wall is a dynamic and regulated system, noxious elements 
such as inflammatory mediators can corrupt normal homeostasis, and pave the way for 
local inflammation.  Vascular cells, such as endothelial and smooth muscle cells, respond 
readily to the prototypical inflammatory mediators interleukin-1 (IL-1) and tumor 
necrosis factor alpha (TNFα).  Surprisingly, these inflammatory agents could also 
activate vascular cells to produce IL-1 and TNFα themselves, in contrast with past 
dogma that solely cells of the immune system produced these cytokines.  Without a 
reliance on immune cells as a source of pro-inflammatory agents, investigation into the 
role of “activated” endothelial and smooth muscle cells in atherogenesis burgeoned 
similar to the current direction that adipocyte-derived inflammation in diabetes 
pathogenesis has progressed (Fig 1.12B). 
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This fundamental research identified several key stimuli and components that 
cultivated the vascular inflammatory process and has potential significance in moderating 
adipose inflammation, including concepts such as: 1) endothelial dysfunction, 2) 
accumulation of modfied lipids within the intima, 3) recruitment of leukocytes to the 
vessel wall, 4) and macrophage accumulation and activation.  
 
Endothelial Dysfunction 
Endothelial dysfunction may also result from exposure to a “toxic” chemical 
environment.  For example, cigarette smoking, abnormal circulating lipid levels, or 
diabetes—all known risk factors for atherosclerosis—can promote endothelial 
dysfunction.  Recent studies indicate that each of these states increases endothelial 
production of reactive oxygen species.  These substances, notably superoxide anion, 
interact with other intracellular molecules to influence the metabolic and synthetic 
functions of the endothelial cell, skewing the cell to pro-inflammatory processes. 
Physical and chemical stressors corrupt normal endothelial homeostasis, creating 
an activated state manifested by 1) impairment of the endothelium’s role as a 
permeability barrier, 2) release of inflammatory cytokines, 3) increased production of 
cell-surface adhesion molecules that recruit leukocytes, 4) altered release of vasoactive 
substances (e.g., prostacyclin and NO), and 5) interference with normal antithrombotic 
properties. These undesired effects of endothelial dysfunction lay the groundwork for 
subsequent events in the development of local inflammation (Fig 1.12B). 
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Lipoprotein Entry and Modification 
The activated endothelium no longer serves as an effective barrier to the passage 
of circulating lipoproteins into the arterial wall (Supplement, Figure 2 summarizes the 
major lipoprotein pathways).  Increased endothelial permeability allows the entry of low 
density lipoprotein (LDL) into the intima where accumulation is enhanced by binding to 
proteoglycans.  This “trapping” increases the residence time of LDL within the vessel 
wall, where the lipoprotein may undergo pro-inflammatory chemical modifications.  
Hypertension, a major risk factor associated with diabetes and a component of the 
metabolic syndrome, promotes retention of lipoproteins in the intima by accentuating the 
production of LDL-binding proteoglycans by smooth muscle cells. 
Oxidation is one type of modification that befalls LDL trapped in the 
subendothelial space. It can result from the local action of reactive oxygen species and 
pro-oxidant enzymes derived from activated endothelial or smooth muscle cells, or from 
macrophages that penetrate the vessel wall.  In diabetic patients with sustained 
hyperglycemia, glycation of LDL may also occur, a derivatization that may ultimately 
render LDL antigenic and pro-inflammatory.  These biochemical modifications of LDL 
act early with initial endothelial dysfunction, but likely promote the persistence of 
inflammation throughout diabetes.  In early endothelial dysfunction and likely throughout 
vascular inflammation, modified LDL (mLDL) promotes leukocyte recruitment and 
macrophage accumulation and activation. 
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Supplement Figure 2: Lipoprotein Transport System,
Lipoproteins ferry water-insoluble fats through the bloodstream. These particles
consist of a lipid core surrounded by more hydrophilic phospholipid, free
cholesterol, and apolipoproteins (also called apoproteins). The apoproteins
present on different classes of lipoprotein molecules are the “conductors” of the
system, directing their lipoprotein payload to specific tissue receptors and also
mediating enzymatic reactions essential for proper distribution.
Five major classes of lipoproteins exist, distinguished by their densities, lipid
constituents, and associated apoproteins: chylomicrons, very–low-density
lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density
lipoproteins (LDL), and high-density lipoproteins (HDL). The exogenous and
endogenous lipoprotein pathways are shown above.
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Leukocyte Recruitment 
Recruitment of leukocytes, primarily monocytes and T lymphocytes, to the vessel 
wall requires: 1) luminal expression of leukocyte adhesion molecules (LAM) to the 
normally non-adherent endothelial surface, and 2) chemoattractant signals (e.g., MCP-1, 
IL-8, IP-10) to direct diapedesis into the subintima.  Two major subsets of LAM persist 
in the inflamed vessels: the immunoglobulin gene superfamily (particularly vascular cell 
adhesion molecule-1 [VCAM-1] and intercellular adhesion molecules-1 [ICAM-1]) and 
the selectins (particularly E- and P-selectin).  
Indeed, ex vivo monocyte adhesion studies using aortic endothelial cells from the 
db/db mouse demonstrated enhanced monocyte adhesion via ICAM-1 and VCAM-1, 
suggesting that diabetic endothelium may be pre-activated.257  Many relevant agonists 
related to diabetic physiology have been shown to upregulated leukocyte adhesion 
molecules, including high glucose exposure, high fat diet, and AGE.258-260  Beyond these 
agonists that may work through common ROS reactions, adipokines may also play a 
direct role as resistin induces EC activation (as gauged by endothelin release) with 
coordinate expression of VCAM-1 adhesion molecules and the MCP-1 chemokine. 261  
Whereas, adiponectin attenuates both resistin- and TNFα- mediated expression of 
endothelial ICAM-1, VCAM-1, and E-Selectin.262,263  Furthermore, adiponectin-deficient 
animals demonstrate enhanced in vivo leukocyte adhesion visualized by intravital 
microscopy.264  Modified LDL (mLDL) and pro-inflammatory cytokines (e.g., IL-1, 
TNFα) can induce LAM and chemokine expression independently; however, mLDL also 
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potently stimulates endothelial- and smooth muscle-derived pro-inflammatory cytokines, 
thus reinforcing any direct action.  This dual ability of mLDL to promote inflammation 
directly or indirectly via cytokines is likely a persistent concept in the diabetic patient, 
thus making it difficult to parse out lipid and non-lipid effects. 
 
Macrophage Accumulation and Activation 
Identification that macrophages accumulate in adipose tissue commensurate with 
weight gain generated new interest in the macrophage as a potent source of inflammatory 
stimuli.265-267  Engendering interest in macrophage-derived inflammatory signals in 
adipose, it has been found that macrophage chemokine signaling is enhanced with 
adiposity, while interruption in chemokine signaling, such as in the CCR2-MCP-1 
receptor-ligand pair, results in diminished macrophage infiltration and improved insulin 
sensitivity.148,268,269  Demonstrating enhanced MCP-1 content in high fat diet fed mice, 
Kanda et al. further observed that loss of MCP-1 through genetic knockouts and 
expression of dominant-negative mutants were able to reduce insulin resistance and 
hepatic steatosis in both diet and genetic models of obesity.268  Conversely, 
overexpression of MCP-1 in adipose tissue under the aP2 promoter was sufficient to 
induce insulin resistance with enhanced hepatic triglyceride content.268 
However, presence alone may not predict pathogenicity as adipose-resident 
macrophages can be “alternatively activated” and “classically activated”, which differ in 
their pro-inflammatory potential 270,271  In fact, it is believed that macrophage recruitment 
to atherosclerotic sites is intended to be beneficial with the ability of macrophage to 
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imbibe excess lipids.  However, lipid overload leads to macrophage conversion to pro-
inflammatory foam cells.  Foam cells cannot form from uptake of LDL through the 
“classical” LDL-receptor, as intracellular cholesterol exquisitely suppresses the 
expression of this pathway.  Also, the “classical” LDL-receptor does not recognize 
mLDL.  Therefore, macrophages rely on a family of “scavenger” receptors that 
preferentially bind and internalize mLDL.  However, unlike classical LDL receptors, 
macrophages that ingest mLDL through scavenger receptors evade negative feedback 
inhibition and permit engorgement of the cell as it fills with the cholesterol-rich lipid.  
Such lipid-laden scavenger cells, also known as “foam cells,” may initially serve a 
salutary role by sequestering potentially pro-inflammatory mLDL constituents and 
removing them from the plaque.  However, impaired efflux of foam cells may lead to 
local accumulation and persistence, mitigating the foam cells’ protective role as the 
“clean-up crew” and instead becoming active sources of pro-inflammatory cytokines.  
The formation of foam cells in adipose tissue has not been identified; however, given the 
surplus of mLDL either from excess oxidation or glycation in the diabetic patient, it 
should be an attractive area of study in macrophage activation and its role in adipose 
inflammation. 
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The superior doctor prevents disease;
The mediocre doctor attends to impending disease;
The inferior doctor treats full-blown diseases.
- Huang Di Neijin
Calligraphy by Ge Jiyun, wife of Han Xu, former Chinese ambassador to the US
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